2018 Thrombosis and Hemostasis Summit of North America (THSNA 2018)


Printable Program




March 6-8, 2018

San Diego, CA






Wednesday, April 3, 2024


12:00 - 5:30 PMChicago Promenade
Registration

1:00 - 5:00 PMChicago Ballroom VII
Platelet Disorder Support Association (PDSA) Pre-Summit Workshop

Join PDSA for lunch and three fascinating presentations on Thrombocytopenia and Thrombosis: risk factors and underlying mechanisms with speakers Howard A. Liebman MA, MD, Professor of Medicine and Pathology, Keck School of Medicine, University of Southern California, and Ishac Nazy, Ph.D., Associate Professor at McMaster University, Hamilton, Ontario, Canada.

How Does ITP Happen? Old and New Mechanisms Thrombosis in ITP, An Often-Unexpected Complication in a Major Acquired Bleeding Disorder Thrombocytopenic and Thrombotic Syndromes Post-Vaccination for COVID-19

Lunch will be provided to workshop registrants.


1:00 - 5:00 PMChicago Ballroom VI
Hematology Workshop: Navigating Complex Cases in Bleeding Disorders

TSHNA Hematology Workshop aims to tackle some of the more challenging and contemporary issues in bleeding disorders. This workshop is structured to provide an in-depth understanding of the topics through presentation of complex cases and dynamic panel discussions. Participants will emerge with enhanced clinical acumen, problem-solving skills, and the ability to apply theoretical knowledge in practical, real-world scenarios. This workshop is ideal for trainees and early-career physicians. The workshop is hosted by Association of Hemophilia Clinic Directors of Canada (AHCDC).


1:00 - 5:00 PMChicago Ballroom IX-X
Pre-Summit Workshop: Interesting Coagulation Cases

Hosted by NASCOLA and ISLH Interesting and challenging cases in coagulation will be presented. Audience participation will be encouraged.


1:00
Welcome & Intro From Islh And Nascola

1:10
Case 1
Cathy Hayward
McMaster University

1:35
Case 2
Kristi Smock
University of Utah and ARUP Laboratories

2:00
Case 3
Rae Kerlin
Ohio State University

2:25
Case 4
Marian Rollins-Raval
University of New Mexico and Tricore Laboratories

2:50
Break

3:10
Case 5
Nicole Zantek
University of Minnesota

3:35
Case 6
Karen Moser
University of Utah and ARUP Laboratories

4:00
Case 7
Sean Yates
UT Southwestern

4:25
Case 8
Jing Jin
Stanford University

4:50
Concluding Remarks



Thursday, April 4, 2024


6:45 - 6:30 PMChicago Promenade
Registration

7:15 - 8:15 AMChicago Ballroom VI
Ready, Set, Go! Shape the Future of Care in von Willebrand Disease (Sponsored by Octapharma)

Join our distinguished faculty; Dr Veronica Flood, Dr Jill Johnsen, and Dr Shveta Gupta to explore the future of care in von Willebrand disease. The panel will discuss the diagnosis of von Willebrand disease, including identification of iron deficiency and genotyping, and the importance of prophylaxis in VWD patients. The results of the WIL-31 study will be presented, the largest prospective prophylaxis study in von Willebrand disease with an on-demand run-in study as an intra-individual patient comparator. We look forward to seeing you in Chicago!


Chair(s): Veronica Flood
7:15
Welcome And Introduction
Veronica Flood

7:20
Identifying And Addressing Unmet Patient Needs In Vwd
Veronica Flood

7:35
Insights From The Largest Prospective Prophylaxis Study In Vwd: Wil-31
Shveta Gupta

7:50
Vwd Genotyping: Empowering Precise Diagnosis And Personalized Care
Jill Johnsen

8:05
Q&A And Concluding Remarks

7:15 - 8:15 AMChicago Ballroom IX-X
Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment, including the latest data in infants: Join the conversation with Dr. Mike Silvey (Sponsored by Genentech)

Please join us for an engaging program led by Dr. Mike Silvey as he shares his perspectives on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal efficacy and safety data that is the foundation of the ongoing clinical trial program in patients with and without FVIII inhibitors, including an overview of real-world experience. He�ll also share updates from the latest trial in infants and previously untreated patients. The presentation will feature brain teasers, showcase social media that�s engaging the hemophilia community, and Mythbuster polls. Be sure to bring your questions to the Q&A following the program.


8:30 - 9:45 AMSheraton Ballroom IV-V
The Rise of the Patient Advocate - Impacting Research, Treatment, and Outcomes

Chair(s): Lena Volland
8:30
How The Clues And Pep Surveys Changed The Mental Health Landscape For Patients And Hcp'S
Rushad Patell

8:55
The Role Of Social Media In Educating The Patients And Clinicians
Lelise Lake

9:20
The Role Of Patient Advocacy Groups In Driving Innovation
Maria Santaella

9:45 - 10:30 AMRiverwalk AB
Posters/Exhibits/Break

Coffee break sponsored by Spark Therapeutics, Inc.


P101
Unfractionated Heparin Use In The Setting Of Acute Pulmonary Embolism
David Scott1, Zhongyuan Chen1, Aniko Szabo1, Lindsay Hammons1, Lisa Baumann Kreuziger1,2
1Medical College of Wisconsin, Milwaukee, WI, United States, 2Versiti Blood Center

P102
In Vivo Volume Electron Microscopy Analysis At The Single Cell Level Reveals Regional Increases In Platelet Shape Dispersity Across A Mouse, Jugular Vein Puncture Wound Thrombus
Madhavi A. Ariyarathne1, Irina D. Pokrovskaya1, Oliver S. Zhao2, Richard D. Leapman2, Maria A. Aronova2, Brian Storrie1
1University of Arkansas for Medical Sciences, Little Rock, AR, United States, 2National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, United States

P103
Long-Term Efficacy And Safety With Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib In Patients With Immune Thrombocytopenia
David J Kuter1, Terry Gernsheimer2, Waleed Ghanima3, Umer Khan4, Brad Ward5, Ahmed Daak5, Nichola Cooper6
1Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, 2University of Washington Medical Center, Seattle, WA, United States, 3Østfold Hospital Foundation, Gralum, Norway, 4Biostatistics, Sanofi, Bridgewater, NJ, United States, 5Sanofi, Cambridge, MA, United States, 6Department of Medicine, Hammersmith Hospital, London, United Kingdom

P104
Risk Factors Associated With Venous Thromboembolism In Chronic Lymphocytic Leukemia
Ambarina Faiz1, Shuang Guo1, Ashwin Sridharan1, Yong Lin2, 3, Claire Philipp1
1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, United States, 2Rutgers School of Public Health, Piscataway, NJ, United States, 3Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States

P105
Outcomes And Predictors Of Immune Thrombocytopenia In Hospitalizations For Antiphospholipid Syndrome: A Nationwide Inpatient Sample Analysis
Michael Imeh1, Ani Gvajaia1, Chukwunonye Amaeshi2, Fidelis Uwumiro3
1Lincoln Medical and Mental Health Centre, Bronx, NY, United States, 2Montefiore Medical Centre, Bronx, NY, United States, 3University of Benin Teaching Hospital , Benin, Nigeria

P106
The P.D1472H Polymorphism In The Vwf Gene Is Common In Indian Patients
Ritika Sharma, Manu Jamwal, Harikishen Senee, Narender Kumar, Arihant Jain, Pankaj Malhotra, Deepak Bansal, Reena Das, Jasmina Ahluwalia
Postgraduate Institute of Medical Education and Research, Chandigarh, India

P107
Iron Deficiency Has Generally Not Been Considered When Defining Sex-Based Hemoglobin Reference Intervals: A Systematic Review
Ingrid Blydt-Hansen1, Vidushi Swarup2, Teruko Kishibe3, Carine Bekdache2, Vanessa Giuliano4, Rebecca Sampat2, Rowan Thillaye-Kerr2, Angela Weyand5, Mark Crowther6, Miranda Wozniak7, Grace H Tang8, Michelle Sholzberg8
1Department of Internal Medicine, University of British Columbia, Vancouver, BC, Canada, 2Hematology-Oncology Clinical Research Group, Division of Hematology-Oncology, St. Michael's Hospital, Toronto, Canada , Toronto, ON, Canada, 3Health Sciences Library, St. Michael’s Hospital, Li Ka Shing Knowledge Institute, Toronto, ON, Canada, 4Department of Medicine, University of Toronto, Toronto, ON, Canada, 5Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, United States, 6Department of Medicine, McMaster University, Hamilton, ON, Canada, 7Department of Laboratory Medicine & Pathobiology, Hematological Pathology, University of Toronto,, Toronto, ON, Canada, 8Departments of Medicine, and Laboratory Medicine and Pathobiology, St Michael’s Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, ON, Canada

P108
Coagulation Profile And Clot Stiffness Analysis From Covid-19-Positive Patients Using A Novel Viscoelasticity Testing Technology
Dimitria Bonizol Camasao1,2+, Jose G. Munguia-Lopez1+, Anna Perez5, José A. Correa3, Cedric Schmitt2, Anis Hadj Henni2, Chantal Séguin4, Donald C. Vinh5, Showan N. Nazhat1*
1Department of Mining and Materials Engineering, McGill University, Montreal, QC, Canada, 2Rheolution Inc., Montreal, QC, Canada, 3Department of Mathematics and Statistics, McGill University, Montreal, QC, Canada, 4Department of Medicine, Division of Hematology, McGill University Health Centre, McGill University, Montreal, QC, Canada, 5Department of Experimental Medicine, Division of Infectious Diseases, McGill University Health Centre, McGill University, Montreal, QC, Canada

P109
Impact Of Anticoagulation In Acquired Hemophilia A
Heather Frazier, Sean Dougherty, Kia Salafian, Hillary Maitland
University of Virginia, Charlottesville, VA, United States

P110
Preliminary Findings Of Utilizing Aptt Assay As A Screening Tool For Lupus Anticoagulant
Suhhyun Kim, Daniel Sabath
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States

P111
Timeliness Of Hemostatic Therapy Administration For Patients With Bleeding Disorders In The Emergency Department
Emily Kraft, Vanessa Bourck, Yuxin Zhang, Lisa Duffett, Alan Tinmouth, Tzu-Fei Wang, Roy Khalife
Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada

P112
Evaluation Of Real-World Treatment Patterns And Outcomes In Patients With Von Willebrand Disease Treated Prophylactically With Recombinant Von Willebrand Factor Across Treatment Centers In The United States
Jonathan C Roberts1, Maissaa Janbain2, Jessica R Marden3, Sanjana Sundaresan3, Natalia Nieto4, Bethany Jones4, Jorge Caicedo4
1Bleeding & Clotting Disorders Institute, Peoria, IL, United States, 2Tulane University School of Medicine, New Orleans, LA, United States, 3Analysis Group, Inc., Boston, MA, United States, 4Takeda Pharmaceuticals U.S.A., Inc, Lexington, MA, United States

P113
The Relationship Between Different Pain Measures, Depression, And Social Support And Race And Ethnicity In Persons With Hemophilia.
Maria E Santaella, Matthew Hartnett, Luke Luckey, Cynthia D Nichols
National Bleeding Disorders Foundation, New York, NY, United States

P114
Bleeding Duet: A Case Of Simultaneous Acquired Factor Viii Deficiency And Acquired Von Willebrand Syndrome
Richard Yu1, Mathew Strelau1, Thunisa Shanmugalingham1 , Mackenzie Bowman2, Arnaud Bonnefoy3, Paula James2, Chai Phua1
1University of Western Ontario, Department of Hematology, London, ON, Canada, 2Queens University, Department of Hematology, Kingston, ON, Canada, 3University of Montreal, Department of Hematology, Montreal, QC, Canada

P115
The Impact Of A High-Risk Anticoagulation Prescribing Stewardship Scoring Tool Implementation In An Inpatient Setting
Emma Baker1, John Lindsley1, Ian Watt1, Rakhi Naik2, Michael Streiff2, Jennifer Yui2, Kathryn Dane1
1The Johns Hopkins Hospital Department of Pharmacy, Baltimore, MD, United States, 2Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, United States

P116
Does Unfractionated Heparin Versus Low Molecular Weight Heparin For Thromboprophylaxis Reduce Complications Near Delivery?
Sophia A. Cordes, Hani Faysal, Joaquin A. Calderon, Renxi Li, Sonya T. Gelfand, Mina Felfeli, Haeun Kim, Homa K. Ahmadzia
Department of Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences, Washington, DC, United States

P117
Rivaroxaban In Older Adults With Nonvalvular Atrial Fibrillation: Population-Based Analysis In Response To Updated Beers Criteria
Ghadeer Dawwas1, Adam Cuker2
1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States, 2Department of Medicine, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia , PA, United States

P118
Monitoring Bivalirudin Therapy Using A Bivalirudin-Specific Chromogenic Anti-Iia Assay
Sean G Yates1, Ravi Sarode1, Sarita Paulino1, Ibrahim F Ibrahim2, Lisa K Skariah3
1Department of Pathology, Division of Transfusion Medicine and Hemostasis, University of Texas Southwestern Medical Center, Dallas, TX, United States, 2Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States, 3UT Southwestern Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas, TX, United States

P119
Influence Of Pharmaceutical Industry On Published Clinical Trial Results
Divyanka Kavdikar1, Siddharth Suresh1, Fakiha Siddiqui2, Atul Laddu1, Jawed Fareed2, Arav Raghunathan1, Ishvari Mokadam1
1Global Thrombosis Forum , Suwanee, GA, United States, 2Loyola University , Chicago, IL, United States

P120
Clinical Experience Using Regional Citrate Anticoagulation In Continuous Renal Replacement Therapy In A Neonate With Acute Kidney Failure: Case Report
Jessica Santoyo Cueva1, Luis Ruben Miranda Ramirez1, Michelle Cecilia Arechiga Andrade1, Erendira Reyes Ramirez1
1Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico, 2Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico, 3Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico, 4Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico

10:30 - 11:30 AMSheraton Ballroom I-II
Short Talks - Complications of Disease and Therapy in H&T

Chair(s): Bethany Samuelson Bannow
10:30
Efficacy Of Radiotherapy For Hemostasis In Tumor-Related Bleeding
Emma P. DeLoughery, Byron Wilson, Aaron Grossberg
Oregon Health & Science University, Portland, OR, United States

10:45
Osteoporosis And Fragility Fractures In Hemophilia And Von Willebrand Disease &Ndash; A Large National Claims Database Study
Divyaswathi Citla Sridhar1, Brandi Dupervil2, Laura Schieve2, Sanjay Ahuja3, Marilyn Manco-Johnson4, Roshni Kulkarni5, Suchitra Acharya6, Meera Chitlur7, Patricia Tobase8, Anjali Sharathkumar9, Binh Le2, Mike Soucie2
1University of Arkansas for Medical Sciences/ Arkansas Children's hospital, Little Rock, AR, United States, 2Centers for Disease Control and Prevention, Atlanta, GA, United States, 3Case Western Reserve University, Cleveland, OH, United States, 4Hemophilia & Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 5Centers for Bleeding and Clotting Disorders, Department of Pediatrics, Michigan State University, Lansing, MI, United States, 6Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, New Hyde Park, NY, United States, 7Division of Hematology/Oncology, Children’s Hospital of Michigan, Detroit, MI, United States, 8University of California San Francisco, San Francisco, CA, United States, 9Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa Health Care, Iowa City, IA, United States

11:00
Healthcare Burden Of Venous Thromboembolism In Hospitalized Cancer Patients: Nationally Representative Estimates Using The Largest All-Payer Inpatient Database In The United States
Krish Khurana1, Giuseppe Maiocco2, Nareg H. Roubinian3, Mohammad Hussain2, Waqas Azhar2, Sujitha Ketineni2, Hareena Sangha4, Michael B. Streiff5, Aaron A. R. Tobian5, Ruchika Goel2,5,6
1Southern Illinois School of Medicine P4P program, Springfield, IL, United States, 2Southern Illinois School of Medicine, Springfield, IL, United States, 3Vitalant Research Institute, San Francisco, CA, United States, 4University of Texas Southwestern School of Medicine, Dallas, TX, United States, 5Johns Hopkins University School of Medicine, Baltimore, MD, United States, 6Vitalant Corporate Medical Affairs, Scottsdale, AZ, United States

11:15
Heparin-Induced Thrombocytopenia Among Cancer Hospitalizations: A Ten Year Retrospective Study
Ayobami Olafimihan1, Praise Fawehinmi2, Ekrem Turk1, Gbolahan Olatunji3, Emmanuel Kokori3, Aderinto Nicholas 4, oh youjin1, Chiamaka Nwachukwu5, Shaka Hafeez1
1John H. Stroger Jr Hospital , Chicago, IL, United States, 2Southern Illinois University Edwardsville, Edwardsville, IL, United States, 3University of Ilorin, Ilorin, Nigeria, 4Ladoke Akintola University of Technology, Ogbomosho, Nigeria, 5Tulane University School of Medicine, new orleans, LA, United States

10:30 - 11:30 AMSheraton Ballroom IV-V
Short Talks - Thrombosis - Innovations in AC

Chair(s): Vinai Bhagirath
10:45
Apixaban And Rivaroxaban Versus Warfarin As Atrial Fibrillation Or Venous Thromboembolism Treatment In Severely Obese Patients: A Multicenter Retrospective Analysis
Paul Dobry1,2, Stephanie Edwin1, Susan Szpunar3, Christopher Giuliano1,2
1Department of Pharmacy, Ascension St. John Hospital, Detroit, MI, United States, 2Department of Pharmacy Practice, Wayne State University, Detroit, MI, United States, 3Department of Medical Education, Ascension St. John Hospital, Detroit, MI, United States

11:00
Unraveling The Anticoagulant Functions Of Fv Using Monoclonal Antibodies
Sean Quinn1, Francis Ayombil1, Matthew Bunce1, Rodney M. Camire1,2
1Department of Pediatrics, The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, United States, 2The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States

11:15
The Anticoagulated Trauma Patient In The Wilderness
Emma DeLoughery, Thomas DeLoughery
Oregon Health & Science University, Portland, OR, United States

10:30 - 11:30 AMChicago Ballroom VII
Short Talks - Industry Bleeding - No CME

Chair(s): Julie Jaffray
10:30
Improved Joint Health After Gene Therapy With Dirloctocogene Samoparvovec (Spk-8011) In People With Hemophilia A
Benjamin Samelson-Jones1, Peter Cygan2, Stacy Croteau3, Huyen Tran4, Margaret Ragni5, Jerome Teitel6, John Rasko 7, Spencer Sullivan 8, Jill Moormeier9, Kristina Haley10, Kristen Jaworski11, Amy MacDougall11, Alexander Long 11, Savina Jaeger 11, Tiffany Chang11, Gallia Levy11
1Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 2Department of Medicine, Division of Blood and Vascular Disorders, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, United States, 3Department of Pediatrics, Harvard Medical School, and the Division of Hematology and Oncology, Boston Children’s Hospital, Boston, MA, United States, 4Australian Centre for Blood Diseases, Monash University, Melbourne, Australia, 5Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States, 6St Michael's Hospital Haemophilia Treatment Centre, University of Toronto, Toronto, ON, Canada, 7Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, and the Gene and Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia, 8Mississippi Center for Advanced Medicine, Madison, MS, United States, 9Department of Medicine, UMKC School of Medicine, Kansas City, MO, United States, 10Department of Pediatrics, Oregon Health & Science University, Portland, OR, United States, 11Spark Therapeutics, Inc., Philadelphia, PA, United States

10:45
Prophylactic Treatment Of Acquired Von Willebrand Disease In Non-Human Primates With Vga039, An Anti-Protein S Monoclonal Antibody
Benjamin Kim, Ian Huck, Lilley Leong, Tony Byun, Aline He, Abel Silva, Joanne Chan, Young Cho, Stephen J. Moore, Graham Parry, Sandip Panicker
Vega Therapeutics, Inc., South San Francisco, CA, United States

11:00
Recombinant Adamts13 Prophylaxis In Patients With Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis From The Phase 3B Continuation Study
Paul Coppo1, Parth Patwari2, Björn Mellgård2, Hong Li2, Marie Scully3, Masanori Matsumoto4, Jerzy Windyga5, Thomas L Ortel6, Spero Cataland7, Paul Knöbl8, Ziqiang Yu9, Ana Antun10, Sami Ibrahimi11, Doug Criger2, Linda T Wang2
1APHP.6–Reference Center for Thrombotic Microangiopathies (CNR-MAT), Hôpital St Antoine, Paris, France, 2Takeda Development Center Americas, Inc., Cambridge, MA, United States, 3University College London Hospitals NHS Foundation Trust, London, United Kingdom, 4Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara, Japan, 5Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland, 6Duke University, Durham, NC, United States, 7Department of Internal Medicine, Ohio State University, Columbus, OH, United States, 8Department of Medicine 1, Division of Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria, 9National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China, 10Department of Hematology and Medical Oncology, School of Medicine, Emory University, Atlanta, GA, United States, 11Department of Internal Medicine, Section of Hematology and Oncology, University of Oklahoma Health Science Center, Oklahoma City, OK, United States

11:15
Initial Report Of Part B Phase 1/2 Efficacy And Safety Results For Bruton Tyrosine Kinase Inhibitor Rilzabrutinib In Patients With Relapsed Immune Thrombocytopenia
Nichola Cooper1, A. J. Gerard Jansen2, Jiri Mayer3, Michael D Tarantino4, Remco Diab5, Brad Ward6, Ahmed Daak6, David J Kuter7
1Hammersmith Hospital, London, United Kingdom, 2Erasmus MC, University Medical Center, Rotterdam, Netherlands, 3Masaryk University Hospital, Brno, Czech Republic, 4The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL, United States, 5Sanofi, Rotkreuz, LU, Switzerland, 6Sanofi, Cambridge, MA, United States, 7Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

11:45 - 12:45 PMChicago Ballroom VI
Real-world experiences with ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc- Von Willebrand Factor XTEN Fusion Protein]: A first-in-class treatment option (Sponsored by Sanofi)

Join us for a conversation about the mechanism of extension, pharmacokinetics, efficacy, dosing and safety information from the XTEND-1 clinical trial, as well as real-world clinical cases with ALTUVIIIO. This presentation will feature a live patient perspective.


11:45 - 12:45 PMChicago Ballroom IX-X
More Than Carriers: Recognizing and Managing Women and Girls With Hemophilia (Sponsored by Novo Nordisk)

To highlight Novo Nordisk�s long-standing commitment to women and girls with rare bleeding disorders, this interactive program will discuss the unique challenges women and girls with hemophilia experience and will highlight the serious consequences that may arise in those who are not diagnosed and treated appropriately. Many women and girls are more than carriers, and they may experience added complications during menstruation, pregnancy, labor, and delivery. Practical guidance for managing hemophilia in women and girls will be presented, including available resources for providers and patients


12:45 - 1:30 PMRiverwalk AB
Posters/Exhibits/Break

P201
Longitudinal Changes In Health-Related Quality Of Life (Hrql) During Anticoagulation Therapy In Cancer-Associated Venous Thromboembolism Treatment
Taylor A Hopper1, Eva Ordonez Mazariegos2, Andrea Jimena Morales Arteaga3, Cristhiam M Rojas Hernandez2
1The University of Texas Health Science Center at Houston, Houston, TX, United States, 2The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 3Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Mexico

P202
Platelet Indices In Healthy Pregnancies
Laura M. Dionisio, Giovani M. Favero
State University of Ponta Grossa, Ponta Grossa, Brazil

P203
Prevalence And Outcomes Of Heparin-Induced Thrombocytopenia In Inflammatory Bowel Disease: A Decade Study
Ayobami Olafimihan1, Ekrem Turk1, Praise fawehinmi2, Gbolahan Olatunji3, Emmanuel Kokori3, Aderinto Nicholas 4, Alejandro Vallejo1, Nkechi Akata5, Shaka Hafeez1
1John H. Stroger Jr Hospital , Chicago, IL, United States, 2Southern Illinois University Edwardsville, Edwardsville, IL, United States, 3University of Ilorin, Ilorin, Nigeria, 4Ladoke Akintola University of Technology, Ogbomosho, Nigeria, 5Meharry Medical College, Nashville , TN, United States

P204
Fixed-Dosing Of 4-Factor Prothrombin Complex Concentrate For Reversal Of Anticoagulation: Evaluating The Effectiveness, Safety, And Cost Savings
Amer Al Homssi1, Ryan Lokkesmoe1, Ryan Powers1, Benjamin Jung2, Lisa Baumann Kreuziger3
1Medical College of Wisconsin, Milwaukee, WI, United States, 2Froedtert Health, Milwaukee, WI, United States, 3Versiti Blood Research Institute, Milwaukee, WI, United States

P205
Structured Education For Newly Diagnosed Persons With Von Willebrand Disease: A Hemophilia Treatment Center Quality Improvement Project Abstract
Dominique N. Barclay, Sarah E. Gonzales, Marsha Hurn, Amanda Kilgore, Jesla Ryan, Jonathan C. Roberts, Michael D. Tarantino
Bleeding and Clotting Disorders Institute, Peoria, IL, United States

P206
Safety And Efficacy Of The Anti-Tissue Factor Pathway Inhibitor Marstacimab In Participants With Severe Hemophilia Without Inhibitors: Results From The Phase 3 Basis Trial And Ongoing Long-Term Extension Study
Suchitra S. Acharya1, Davide Matino2, Andrew Palladino3, Eunhee Hwang3, Regina McDonald4, Carrie Turich Taylor5, John Teeter5
1Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, Northwell Health, New Hyde Park, NY, United States, 2McMaster University, 237 Barton St. East, Hamilton, ON, Canada, 3Pfizer Inc, Collegeville, PA, United States, 4Pfizer Inc, New York, NY, United States, 5Pfizer Inc, Groton, CT, United States

P207
Efficacy And Safety Of Eptacog Beta For Bleed Treatment In Adults And Adolescents With Hemophilia B And Inhibitors During Persept 1
Meera Chitlur1, Yasmina Abajas2, Suchitra Acharya3, Sanjay Ahuja4, Jonathan Bernstein5, Elizabeth Bowhay-Carnes6, Brandon Hardesty7, Jonathan C. Roberts8,9, Vanessa Salinas10, Craig Seaman11, Robert Sidonio Jr.12, Daniel Bonzo13, Jim Phipps14, Thomas Wilkinson15, Guy Young16
1Central Michigan University College of Medicine/Children’s Hospital of Michigan, Carmen and Ann Adams Department of Pediatrics, Division of Hematology/Oncology, Detroit, NY, United States, 2Hemophilia and Thrombosis Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 3Cohen Children’s Medical Center, Northwell Health, New Hyde Park, NY, United States, 4Rainbow Babies & Children’s Hospital, Cleveland, OH, United States, 5Hemophilia Center of Central Pennsylvania, Hershey Medical Center, Hershey, PA, United States, 6UT Health San Antonio, San Antonio, TX, United States, 7Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, United States, 8Bleeding & Clotting Disorders Institute, Peoria, IL, United States, 9Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, United States, 10Center for Inherited Blood Disorders, Orange, CA, United States, 11Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, United States, 12Aflac Cancer and Blood Disorders Center and Emory University, Atlanta, GA, United States, 13LFB-USA, Inc., Framingham, MA, United States, 14HEMA Biologics, LLC, Louisville, KY, United States, 15GLOVAL LLC, Broomfield, CO, United States, 16Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, United States

P208
Access To Factor Viii And Factor Ix To Persons With Hemophilia In Arkansas: A Quality Improvement Study
Divyaswathi Citla-Sridhar1, 2, Kara Burge2, Jean Aroom3, Justine Kaplan3, Shelley Crary1, 2
1University of Arkansas for Medical Sciences, Little Rock, AR, United States, 2Arkansas Children’s Hospital, Little Rock, AR, United States, 3American Thrombosis and Hemostasis Network , Rochester, NY, United States

P209
Disease Burden, Quality Of Life, And Treatment Patterns In Patients With Hereditary Factor X Deficiency: Analysis Of Data From The Hereditary Factor X Deficiency In America Survey
Kim Clark1, Denise A. Garner2, Amy Wu2, Lorie Mody2, Jaymin Patel2, Brian Branchford3
1Kedrion Biopharma, INC., Fort Lee, NJ, United States, 2AESARA, INC., Chapel Hill, NC, United States, 3Versiti Blood Research Institute, Medical College of Wisconsin, and Children's Wisconsin, Milwaukee, WI, United States

P210
Elevated Protein C Is Protective Against Post Thrombotic Syndrome
Zijun He1, Vivian Thompson1, Dianne Thornhill1, Rick Shearer1, Christine Baird2, Marilyn Manco-Johnson1
1University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 2University of Colorado Anschutz Medical Campus Research Laboratory, Aurora, CO, United States

P211
Prophylactic Or Post-Traumatic Treatment Of Hypofibrinogenemia And Dysfibrinogenemia With Fibrgya In Eight Clinical Cases
Jessica N. Mistretta, Kristin T. Ansteatt, Michael D. Tarantino
Bleeding and Clotting Disorder Institute, Peoria, IL, United States

P212
Real-World Use Of Recombinant Factor Ix Fusion Protein In Previously Untreated Patients With Congenital Hemophilia B From The Athn 8 Study
Courtney D. Thornburg1, Martin Chandler2, Lynn Malec3, Matthew Manuel2, Carrie O'Neill2, Michael Recht4, 5, Elizabeth Taggart2, Hongseok Kim6, Vidhi Desai6, Hiren Shah6, Shannon L. Carpenter7
1Rady Children’s Hospital San Diego, San Diego, CA, United States, 2American Thrombosis and Hemostasis Network, Rochester, NY, United States, 3Versiti Blood Research Institute, Waukesha, WI, United States, 4Yale University School of Medicine, New Haven, CT, United States, 5National Bleeding Disorders Foundation, New York, NY, United States, 6CSL Behring, King of Prussia, PA, United States, 7Children’s Mercy Hospital, Kansas City, MO, United States

P213
The Effect Of Budd-Chiari Syndrome (Bcs) In Hospitalized Hepatocellular Carcinoma Patients (Hcc): A Nationwide Analysis.
Ekrem G Turk, Ayobami Olafimihan, Khaldun Obeidat, Youjin Oh, Lina James, Angelo Caputi Zuniga, Alejandro Vallejo
John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, United States

P215
Anti-Factor Xi Antibodies Targeting The Apple 2 Domain And The Catalytic Domain Exert Distinct In Vitro Inhibitory Profiles On Coagulation Function
Dan Chalothorn, KehDih Lai, Weizhen Wu, Holly Sorenson, George Ehrlich, Ashique Rafique, Ishita Chatterjee, Kei Saotome, Matthew Franklin, Lori Morton
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

P216
ANtithroMbOsIS STEwardshIP As A Key Driver Within A Vte Center OF ExcelleNCe - Ambition Investigators 
Angela M. Martoccia Grabazs, Preeyaporn Sarangarm, Sundeep S. Guliani, Jonathan L. Marinaro, Allison E. Burnett
University of New Mexico Hospital, Albuquerque, NM, United States

P217
Anticoagulation Stewardship: Appropriate Use Of Apixaban And Rivaroxaban Factor Xa Levels In The Emergency Department
Firas Quran, Sara Zochert, Michael Gulseth, Alicia Martin
Sanford USD Medical Center and Hospital, Sioux Falls, SD, United States

P218
Cellular Indices Of Dvt
Priyanka Kavdikar1, Ragini Mohan1, Neha Thomas1,3, Fakiha Siddiqui2, Atul Laddu1, Jawed Fareed2, Nysha Reddy1
1Global Thrombosis Forum , Suwanee, GA, United States, 2Loyola University , Chicago, IL, United States, 3University of Westminster, London, United Kingdom

P219
Are Medical Learners Adept At Recognizing Heavy Vaginal Bleeding?
Fartoon M Siad1, Andrea Lausman2, Filomena Meffe2, Carolyn Snider3, Martina Trinkaus1,4, Michelle Sholzberg1,4
1Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Department of Obstetrics and Gynecology, Toronto, ON, Canada, 3Division of Emergency Medicine, Toronto, ON, Canada, 4Division of Hematology/Oncology, St. Michael’s Hospital, Toronto, ON, Canada

1:30 - 3:00 PMSheraton Ballroom I-II
Identification and management of acquired bleeding in the acute care setting

Chair(s): Bethany Samuelson Bannow
1:30
Review Of Aquired Factor Deficiencies
Davide Matino

2:00
Laboratory Tools To Identify Acquired Coagulation Factor Abnormalities
Kristi Smock

2:30
Management Considerations In The Surgical Setting Of Suspected Aquired Factor Deficiencies
Rebecca Kruse-Jarres

1:30 - 3:00 PMSheraton Ballroom IV-V
Unbiased tech approaches for hematological discoveries

Chair(s): Jordan Shavit
1:30
Deep Mutational Scanning To Probe Function Of Coagulation Proteins
Laura Haynes

2:00
Genetic Engineering Of Megakaryocytes To Uncover Functions Of Platelet Proteins
Jesse Rowley

2:30
Mass Spectrometry Glycomics And Determination Of Gpib Glycosites
Marie Hollenhorst

1:30 - 3:00 PMChicago Ballroom VII
Taking the result to the patient - laboratory considerations in thrombosis

Chair(s): William Dager
1:30
Laboratory Considerations On Doac Levels (Including Precision And What We'Ve Learned From External Qa&Semi; Comment On Andexanet)
Jim Zehnder

2:00
Doac - When To Measure Levels And How To Interpret: On-Treatment Vs Therapeutic Range
Deb Siegal

2:30
Advances In Testing For Aps - Beyond Sapporo (Titres, Isotypes, Non-Criteria Antibodies)
Tom Ortel

3:00 - 3:45 PMRiverwalk AB
Posters/Exhibits/Break

P301
Novel Point-Of-Care (Poc) Platform For Direct Oral Anticoagulants (Doac) And Vitamin K Antagonists (Avk) Testing: Microdoac And Microinr Assays
Tamara Montes, Mikel Santiago, Irene Mijangos
R&D Department, iLine Microsystems S.L., San Sebastián/Donostia, Spain

P302
Red Blood Cell Haemolysis And Platelet Activation : The Forgotten Players Of Hypercoagulability
Neha Thomas, Stipo Jurcevic
University of Westminster, London, United Kingdom

P303
Hmb-001 For Prophylactic Treatment Of Glanzmann Thrombasthenia: Phase 1/2 Trial Insights
Suthesh Sivapalaratnam1,2, Gillian Lowe3, Ashley Gosnell4, Ulrike Lorch5, Jigar Amin4, Catherine Rea4
1Queen Mary University of London, London, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom, 3Comprehensive Care Haemophilia Centre, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 4Hemab Therapeutics, Cambridge, MA, United States, 5Richmond Pharmacology, London, United Kingdom

P304
Investigating The Relationship Between D Dimer Levels And Viscoelastic Characteristics Of Blood Clots
Eli J Foster, Nathaniel Hai, Seemantini K Nadkarni
Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

P305
Transfusion Trends In The Obstetric Population With Analysis Of A Soft Stop Transfusion Emr Alert
Maren Plant1, Sophia Cordes1, Caroline Bereuter1, Jaclyn Phillips1, Xiomara Fernandez2, Homa Ahmadzia1
1Department of Obstetrics and Gynecology, George Washington University , Washington, DC, United States, 2Department of Pathology, George Washington University, Washington, DC, United States

P306
The Burden Of Hemophilia In The Us: Methods And Results From The Cost Of Hemophilia: A Socioeconomic Survey (Chess) Us (2022)
Randall Curtis1, Maria Elisa Mancuso2,3, Enrico Ferri Grazzi4, Donna Coffin5, Brian O'Mahony6,7, Clive Smith8, Daniél Anibal García Diego9, Matteo Arzenton10, Thomas Sannié11, Fiona Brennan12, Tom Burke4,13, Sarah Brighton4
1Hematology Utilization Group Study (HUGS), Walnut Creek, CA, United States, 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Italy, 3Humanitas University, Pieve Emanuele, Milan, Italy, 4HCD Economics, Knutsford, United Kingdom, 5World Federation of Hemophilia, Montreal, QC, Canada, 6Irish Haemophilia Society Ltd, Dublin, Ireland, 7Trinity College, Dublin, Ireland, 8The Haemophilia Society, London, United Kingdom, 9Federación Española de Hemofilia (FedHemo), Madrid, Spain, 10Italian Federation of Haemophilia Associations (FedEmo), Rome, Italy, 11Association Française des Hémophiles (AFH), Paris, France, 12Faculty of Health and Social Care, University of Chester, Chester, United Kingdom

P307
Hemostatic Outcome Of Surgical Procedures In Patients With Hemophilia Receiving Concizumab Prophylaxis: Data From The Phase 3 Explorer7 And Explorer8 Trials
Matthew Evans1, Anthony K.C. Chan2, Chris Barnes3, Mary Mathias4, Silvia Linari5, Francisco-José López-Jaime6, Lone Hvitfeldt Poulsen7, Julien Bovet8, Jan Odgaard-Jensen8, Tadashi Matsushita9, Emily K. Waters10
1Penn State Health Milton S. Hershey Medical Center, Hershey, PA, United States, 2McMaster Children’s Hospital, McMaster Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada, 3Royal Children’s Hospital Melbourne, Victoria, Australia, 4Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, 5Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy, 6Hospital Regional Universitario de Málaga, Málaga, Spain, 7The Haemophilia Centre, Department of Haematology, Aarhus University Hospital, Aarhus, Denmark, 8Novo Nordisk A/S, Søborg, Denmark, 9Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan, 10Novo Nordisk Inc., Plainsboro, NJ, United States

P308
Athn Transcends &Ndash; Hemophilia Gene Therapy Outcomes Arm: A Long-Term Follow-Up Study On Safety And Effectiveness Of Gene Therapy In People With Hemophilia
Staber Janice1, Blanca Salazar2, Roberto Guillen-Gonzalez2, Michael Recht3,4, Tammuella Chrisentery-Singleton5, Ulrike Reiss6
1Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Children’s Hospital, Iowa City, IA, United States, 2CSL Behring, King of Prussia, PA, United States, 3National Bleeding Disorders Foundation, New York, NY, United States, 4Yale University School of Medicine, New Haven, CT, United States, 5American Thrombosis and Hemostasis Network, Rochester, NY, United States, 6Hemophilia Treatment Center St. Jude’s Children’s Research Hospital, Memphis, TN, United States

P309
A Phase 3, Randomized, Active-Control Study Of Four-Factor Prothrombin Complex Concentrate Versus Frozen Plasma In Bleeding Adult Cardiac Surgery Patients
Keyvan Karkouti1,2, Jeannie Callum3,4, Kenichi Tanaka5, Deep Grewal2, Cristina Solomon6, Sigurd Knaub6, Sylvia Werner7, Gita Pezeshki7, Jerrold H. Levy8
1University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Queen’s University, Kingston, ON, Canada, 4Kingston Health Sciences Centre, Kingston, ON, Canada, 5University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States, 6Octapharma AG, Lachen, Switzerland, 7Octapharma USA, Paramus, NJ, United States, 8Duke University School of Medicine, Durham, NC, United States

P310
Vitamin D Deficiency In Persons With Bleeding Disorders &Ndash; A Single Center Experience
Dan Leary, Mindy Simpson, Lisa Boggio
Rush Hemophilia and Thrombophilia Center, Chicago, IL, United States

P311
Genomic Variations In Factor Vii Deficiency Predisposing To Thrombophilia: A Case Of Sinus Venous Thrombosis In A Patient With Factor Vii Deficiency
Aaron C. Lobo 1, Paridhi Ghai1, Fabricio M Webber1, David H. Witt2
1Bridgeport Hospital/Yale New Haven Health , Bridgeport, CT, United States, 2Yale Smilow Cancer Center/Yale school of Medicine, Trumbull, CT, United States

P312
Emicizumab Prophylaxis For The Treatment Of Infants With Severe Haemophilia A Without Factor Viii Inhibitors: Primary Analysis Of The Haven 7 Study
Steven W. Pipe1, Peter Collins2, Christophe Dhalluin3, Gili Kenet4, 5, Christophe Schmitt3, Muriel Buri3, Víctor Jiménez-Yuste6, Flora Peyvandi7, 8, Guy Young9, Johannes Oldenburg10, Maria Elisa Mancuso11, 12, Kaan Kavakli13, Anna Kiialainen3, Markus Niggli3, Tiffany Chang14, Michaela Lehle 3, Karin Fijnvandraat15
1University of Michigan, Ann Arbor, MI, United States, 2School of Medicine, Cardiff University, Cardiff, United Kingdom, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4Sheba Medical Center, Ramat Gan, Israel, 5Tel Aviv University, Tel Aviv, Israel, 6Hospital Universitario La Paz-IdiPaz, Universidad Autónoma, Madrid, Spain, 7Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy, 8Università degli Studi di Milano, Milan, Italy, 9Children’s Hospital Los Angeles, Los Angeles, CA, United States, 10Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany, 11IRCCS Humanitas Research Hospital, Rozzano, Italy, 12Humanitas University, Pieve Emanuele, Milan, Italy, 13Ege University Faculty of Medicine Children's Hospital, Izmir, Turkey, 14Spark Therapeutics, Inc., San Francisco, CA, United States, 15University of Amsterdam, Amsterdam, Netherlands

P313
A Multi-Year Follow-Up Study Of Fidanacogene Elaparvovec Gene Therapy For Hemophilia B
Benjamin J. Samelson-Jones1,2, Lindsey A. George1,2, John E. J. Rasko3,4, Adam Giermasz5, Jerome M. Teitel6, Catherine E. McGuinn7, Jonathan M. Ducore5, Sharon Pennington8, Katherine A. High2, Jeremy Rupon9, Francesca Biondo10, Annie Fang11, Lynne M. Smith9, Matko Kalac11, Amit Chhabra11, Frank Plonski9
1Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States, 3Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney, Australia, 4Gene and Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia, 5Hemophilia Treatment Center, University of California Davis, Sacramento, CA, United States, 6St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, 7Weill Cornell Medicine, New York, NY, United States, 8Mississippi Center for Advanced Medicine, Madison, MS, United States, 9Pfizer Inc, Collegeville, PA, United States, 10Pfizer Srl, Rome, Italy, 11Pfizer Inc, New York, NY, United States

P314
Emergency Department Utilization In A Patient Cohort With Hemophilia: A Single Centre Experience
Kelsey Uminski1,2, Natalia Rydz1,2, Dawn Goodyear1,2
1Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Calgary, AB, Canada, 2Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Calgary, AB, Canada

P315
Dual Direct Oral Anticoagulant Therapy In Challenging Thrombosis: A Case Series
Heather McPhaden1, Chornenki Nicholas1, Peterson Erica1, Lai Chieh Min Benjamin1,2, Lee Agnes1
1The University of British Columbia, Department of Medicine, Division of Hematology, Vancouver, BC, Canada, 2The University of British Columbia Centre for Blood Research, Vancouver, BC, Canada

P316
Recurrent Venous Thromboembolism In A Symptomatic Hemophilia A Carrier
Natalie/A Montanez1,3, Joanna/M Larson1,3, Miguel/A Escobar1,2,3
1University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, United States, 2University of Texas Health Science Center of Houston, McGovern Medical School, Department of Internal Medicine, Houston, TX, United States, 3Gulf States Hemophilia and Thrombophilia Center , Houston, TX, United States

P317
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Study Of Human Plasma Derived Antithrombin (Atenativ) In Heparin-Resistant Cardiac Surgery Patients
Cristina Solomon1, Catrin Argyle1, Jerrold H. Levy2, Sylvia Werner1
1Octapharma AG, Lachen, Switzerland, 2Duke University School of Medicine, Durham, NC, United States

P318
An Implementation Dilemma: Rejection Of Thromboprophylaxis Recommendations In The Children&Rsquo;S Likelihood Of Thrombosis (Clot) Trial
Shannon C. Walker, Benjamin French, Ryan P. Moore, Henry J. Domenico, C. Buddy Creech, Amanda S. Mixon, Daniel W. Byrne, Allison P. Wheeler
Vanderbilt University Medical Center, Nashville, TN, United States

P319
Overcoming Distance And Travel Barriers For Virginia Bleeding Disorders Treatment Centers: A Comprehensive Needs Assessment
Erika J Martin, Lauren C Dunn, Katherine L Bains, Janice G Kuhn
Virginia Commonwealth University, Richmond, VA, United States

P320
Doac&Rsquo;S In The Elderly
Abhinav Paknikar1, Keerti Chakravarthy1, Fakiha Siddiqui2, Atul Laddu1, Jawed Fareed2, Aarushi Dua1, Anish Joshi1
1Global Thrombosis Forum , Suwanee , GA, United States, 2Loyola University , Chicago , IL, United States

3:00 - 5:00 PMOnline
Online Poster Session

P801
The Role Of Fibrinogen In Changing The Hemostasis Of Patients With Neoplasia And Their Influence On The Microcirculatory Bed Of The Lungs And Control By Anticoagulants
Vira A. Barilka, Volodymyr L. Matlan, Sofia V. Prymak, Olha O. Shalay, Vasyl L. Novak
SI "Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine" Lviv Ukraine, Lviv, Ukrenia

P802
Antithrombotic Stewardship And Health Equity In Peripheral Artery Disease
Kelly M. Rudd1,2, Kristie K. Roberts1, Cooper M. Hamilton2
1Oklahoma State University Center for Health Sciences Center College of Osteopathic Medicine, Tulsa, OK, United States, 2Oklahoma State University Center for Health Sciences Center College of Osteopathic Medicine, Tahlequah, OK, United States

P803
Platelet Immunophenotype Induced By The Spike (S) Protein And The Rbd Domain Of Sars-Cov-2 Virus.
Alan Cano-Mendez, Nallely Garcia-Larragoiti, Yesenia Ambriz-Murillo, Patricia Guzman-Cansino, Alejandra Ochoa-Zarzosa, Martha Eva Viveros-Sandoval
Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico

P804
Correlation Between Abo Blood Types And Disease Severity In Sickle Cell Anemia: Implications For Thrombosis And Hemostasis.
George M Bassey1, Titilope A Adeyemo1,2, Ann A Ogbenna1,2, Abiola B Bolarinwa1, Ademola S Adewoyin2, Emmanuel Iyere1
1Lagos University Teaching Hospital , Lagos, Nigeria, 2College of Medicine University of Lagos, Lagos, Nigeria

P805
The Prevalence Of Thrombotic Events Reported Following Sars-Cov2 Vaccine Receipt: Data From The Itp Natural History Study Registry
Jennifer DiRaimo1, Caroline Kruse1, Kate Foster1, Alexandra Kruse1,2, Howard Liebman3, Craig Kessler4
1Platelet Disorder Support Association, Cleveland, OH, United States, 2Tulane University School of Medicine, New Orleans, LA, United States, 3Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Norris Comprehensive Cancer Center, Los Angeles, CA, United States, 4Vincent Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States

P806
Investigating Inter-Assay Variability Between Doac Calibrated Anti-Factor Xa Assays: A Substudy Of The Pause Trial
Ryan Baker1, Rita Selby2,3, Karen A. Moffat4,5, Melanie St John5, Alex C. Spyropoulos6,7,8, Sam Schulman9, James Douketis9
1Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 3Department of Medicine, University of Toronto, Toronto, ON, Canada, 4Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada, 5Department of Medicine, McMaster University, Hamilton, ON, Canada, 6The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States, 7Institute of Health System Science - The Feinstein Institutes for Medical Research, Manhasset, NY, United States, 8Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, NY, United States, 9Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada

P807
Chief: A Retrospective Self-Control Study Of Children <12 With Severe Hemophilia A Without Inhibitors Comparing Emicizumab To Fviii
Daniel Mashiach1,2, Patrice Mead1, Kendall Carneiro1, Jemily Malvar1, Guy Young1,3
1Children’s Hospital Los Angeles , Los Angeles, CA, United States, 2WesternU College of Osteopathic Medicine of the Pacific, Pomona, CA, United States, 3Keck School of Medicine, University of Southern California, Los Angeles, CA, United States

P808
The Evaluation Of Mrx Pt Doac Assay For Detection Of Clinically Relevant Factor Xa Inhibitor Drug Levels
Brittany MA Salter1, Karen A Moffat1,2,3, Stephen A Carlino3, Liselotte Onelöv4, Sarah Ge1, Marina Atalla1, Raymond Melika1, Saumya Bansal1, Siraj Mithoowani1, Mark Crowther1,2
1Department of Medicine, McMaster University, Hamilton, ON, Canada, 2Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada, 3Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada, 4Nordic Biomarker, Umeå, Sweden

P809
A Retrospective Study Of Acquired Von Willebrand Syndrome In Myeloproliferative Neoplasms
Mohammed Al Sharif 1 ,2, Brian Harnett 3, Subia Tasneem 1, Brian Leber 4 ,5, Christopher Hillis 5, Catherine P.M. Hayward 1 ,3 ,4
1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada, 2 Department of Pathology and Laboratory Medicine, King Abdullah Bin Abdulaziz University Hospital, Princess Nourah University, Riyadh, Saudi Arabia, 3 Department of Medicine, McMaster University, Hamilton, ON, Canada, 4 Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada, 5 Hematology/Oncology, Juravinski Cancer Center, Hamilton, ON, Canada

P810
Development Of A Patient Reported Outcome Measure To Study Quality Of Life In Bleeding Disorder Of Unknown Cause
Callie Berkowitz1, Supreet Goraya2, Alice Ma1, Nigel Key1, Angela Stover3
1Division of Hematology and Blood Research Center, University of North Carolina, Chapel Hill, NC, United States, 2Department of Maternal, Child, and Family Health, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, United States, 3Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, United States

P811
Using A Thrombodynamics Test For Diagnostics Of Hypercoagulation In Cancer Patients And Prediction Of Thromboembolic Complications: Preliminary Research Results.
Irina Dudina1, Ekaterina Koltsova2,3, Irina Nigmatullina1, Yana Akhmadiyarova1, Olga Kostash1, Anna Chankina1, Daniil Stroyakovskiy1
1State Budgetary Healthcare Institution Moscow City Oncology Hospital No. 62 of the Moscow City Health Department, Russian Federation, Moscow, 143515, Moskovskaya area, Krasnogorsk urban district, Istra village, building 27, Moscow, Russia, 2Federal State Budgetary Institution Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation, Russian Federation, Moscow, 117198, Samory Machel street, building 1, Moscow, Russia, 3Federal State Budgetary Institution of Science Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, Russian Federation, Moscow, 109029, Srednyaya Kalitnikovskaya street, building 30, Moscow, Russia

P812
Comparative Analysis Of Bleeding And Thrombotic Risks Among Immune Checkpoint Inhibitors: Insights From The Fda Adverse Event Reporting System
Emily L Paton1, Emma P Deloughery1,2
1Oregon Health & Science University, Department of Medicine, Portland, OR, United States, 2Oregon Health & Science University, Department of Medicine, Division of Hematology & Medical Oncology, Portland, OR, United States

P813
Acquired Hemophilia Secondary To The Transplantation Of Hematopoietic Progenitors. A Systematic Review
Rafael Pichardo-Rodriguez1, Cristhian Gonzales- Rospigliosi1, Dalia Pimentel-Ramirez1, Aracely Carrasco-Espinoza1, Lara Vela-Rojas1, Diana-Cristina Ramírez-Meyhuay1, Jhony A. De La Cruz-Vargas1, Alfredo Wong Chang2, Cristobal Frutos3
1Instituto de Investigaciones en Ciencias Biomédicas (INICIB). Universidad Ricardo Palma, Lima, Peru, 2Unidad de Trasplante de Médula Ósea. Hospital Nacional Edgardo Rebagliati-Essalud, Lima, Peru, 3Instituto de Previsión Social, Asuncion, Paraguay

P814
Effect Of Acute Deep Vein Thrombosis In Patients With Lung Cancer In Acute Deep Vein Thrombosis (Dvt): A Study Of The Nation Inpatient Sample
Maria Cristina Cuartas- Mesa, Nana Yaa Ampaw, Edwin Gwira- Tamattey, Enrique Martinez- Trevino, Alejandro Nieto- Dominguez , Ekrem Turk
John H. Stroger, Jr. Hospital of Cook County, Chicago , IL, United States

P815
Gathering And Disseminating Standardized Gene Therapy Data &Ndash; The World Federation Of Hemophilia Gene Therapy Registry
Barbara A. Konkle1, Flora Peyvandi2, Mayss Naccache3, Wolfgang Miesbach4, Brian O'Mahony5, Steven W. Pipe6, Mark W. Skinner7, Donna Coffin3, Glenn F. Pierce3
1University of Washington, Seattle, WA, United States, 2Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, 3World Federation of Hemophilia, Montreal, QC, Canada, 4University Hospital Frankfurt, Frankfurt, Germany, 5Irish Haemophilia Society, Dublin, Ireland, 6University of Michigan, Ann Arbor, MI, United States, 7Institute for Policy Advancement Ltd, Washington, DC, United States

P816
Predicting Pulmonary Embolism In Patients With Deep Venous Thrombosis In The Emergency Department: A Quantitative D-Dimer Diagnostic Approach From A Hospital In Mexico City
Oscar A Lopez Ramos1, David G Gonzalez Sanchez 2, Oliver A Gomez-Gutierrex2, Hector Segura Marin2, Andrea Rojas Guevara 1, Arely Gayosso Godinez 1
1Hospital Español , Mexico City , Mexico, 2Tecnologico de Monterrey , Monterrey , Mexico

3:45 - 5:15 PMSheraton Ballroom I-II
Health Care Inequitity in the Treatment of VTE

Chair(s): Anne Rose
3:45
Disparities In Anticoagulation Care Across The Spectrum
Sara Vasquez

4:15
Treatment Of Vte In Rural America
Jennifer Young

4:45
Maternal Mortality And Pulmonary Embolism In Minority Populations
Leslie Lake

3:45 - 5:15 PMSheraton Ballroom IV-V
Take a hike Mickey- novel T&H insights from non-murine animals

Chair(s): Bobby Lee
3:45
Multispecies Analysis Of The Erad Pathway In Platelet Function
Anna Dahlgren

4:15
Deciphering Platelet Cold Storage Lesion In Hibernating Rodents
Scott Cooper

4:45
Discovering Novel Pro-Coagulant Agents From Snake Venom
Raymond Adili

3:45 - 5:15 PMChicago Ballroom VII
Lab support of clinical decision-making in the critically ill bleeding patient

Chair(s): Marian Rollins-Raval
3:45
How The Lab Can Support Clinical Decision-Making In Acute Critical Bleeding
Nathan Nielsen

4:15
Review Of The Use Of Concentrated Clotting Factors Versus Blood Products
Laura Downey

4:45
Coagulation Biomarkers And Laboratory Support Of Critically Ill Patients
Sabrina Racine-Brzostek

5:30 - 6:30 PMChicago Ballroom VI
Clinical & Patient Perspective: A Treatment for Adults with Acute Hepatic Porphyria, including Acute Intermittent Porphyria (Sponsored by: Alnylam Pharmaceuticals)

Acute hepatic porphyria (AHP) is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. Led by Dr. Lisa Boggio, a consultant of Alnylam Pharmaceuticals, this presentation will provide a disease overview and review the clinical profile of a treatment for adults with AHP, featuring Phase 3 Study results and open-label extension data.

Attendees will also hear from an AHP patient who will share their experience with the disease and treatment.

Please join Alnylam Pharmaceuticals and Dr. Boggio to learn more about this treatment for adults with AHP. Dinner will be provided for attendees.


5:30 - 6:30 PMChicago Ballroom IX-X
Gene Therapy for Hemophilia B: Sharing Experiences in Real-World Settings (Sponsored By: CSL Behring)

Despite meaningful improvements in treatment for hemophilia B, there remains a need for new therapeutic options that will reduce bleeds, reduce or eliminate the need for routine factor IX prophylaxis, and provide long-term benefits of sustained factor IX activity levels. The first ever FDA-approved gene therapy for hemophilia B is designed to reduce the burden of disease on patients� lives by addressing these unmet needs.

Join our educational product theater session as a team of hemophilia B experts discuss the clinical data and the patient and HCP journey towards treatment as well as share their clinical experiences with gene therapy for hemophilia B.

Continuing education credits will not be offered for this program.


7:00 - 8:00 PMOnline
On-Demand Workshop



Friday, April 5, 2024


6:30 - 8:00 PMChicago Promenade
Registration

7:00 - 8:00 AMChicago Ballroom VI
Advances in iTTP management - Contemporary Clinical Approaches (Sponsored by Sanofi)

Please join our Sanofi Medical Affairs Rare Blood Disorders team for our medical symposium to gain expert insights on prioritizing clinical management of aTTP/iTTP, focusing on early treatment, and achieving durable responses from therapies, ultimately resulting in improved clinical outcomes. The symposium will be presented in two parts and will illustratively describe the iTTP pathophysiology, epidemiology/diagnostic considerations, before discussing the ISTH guidelines on diagnosis and treatment of iTTP and important implications on clinical management of iTTP.


7:00 - 8:00 AMChicago Ballroom IX-X
Hemostasis 2.0: Rethinking Hemophilia Management and Monitoring with Anti-TFPIs and FVIII Mimetics (In partnership with CME Outfitters, LLC. Supported by an educational grant from Novo Nordisk, Inc.)

In this CME Outfitters live activity, experts in hemophilia, including a patient who has lived with the disorder for many years, discuss the role of these newer therapies, how they work, and how to implement them in practice to improve quality of care and outcomes. A focused exercise in shared decision making keeps the conversation grounded in counseling and care and includes both clinician and patient perspectives.

This activity is certified for 1.0 hours of ACCME, ANCC, AAPA, and ABIM MOC II credit.


8:15 - 9:45 AMSheraton Ballroom I-II
Not your mom's jeans: Updates on Gene therapy for Hemophilia patients

Chair(s): Allison Wheeler
8:15
Considering Gene Therapy In The Context Of New Options For Management Of Hemophilia
Ben Samelson-Jones

8:45
Liver Disease In The Era Of Gene Therapy
Ype P De Jong

9:15
Managing Medical Challenges Of Gene Therapy
Stacy Croteau

8:15 - 9:45 AMSheraton Ballroom IV-V
FXI & FXII

Chair(s): William Dager
8:15
Contact Inhibiton In Ecmo
Joe Palumbo

8:45
Role Of Antiplatelet And Anticoagulant Therapy In Veno-Occlusive Crisis (Voc)
Erica Sparkenbaugh

9:15
State Of The Art On Fxi And Fxii Inhibitor Data
Jeff Weitz

8:15 - 9:45 AMChicago Ballroom VII
Evolution of the Clinical Hemostasis/Thrombosis Laboratory

Chair(s): Karen Moser
8:15
Evolution Of Hemostasis/Thrombosis Laboratory Physician Role--Clinical Consultant
Evelyn Cortina

8:45
Evolution Of Hemostasis/Thrombosis Laboratory Professional Role At The Bench
Jing Jin

9:15
Evolution Of Hemostasis/Thrombosis Laboratory Methods Including Laboratory Automation (Elisa-->Lia, Manual-->Automated Adamts13, On-Demand Vs. Batch Testing, New Von Willebrand Assays)
Rusty Higgins

9:45 - 10:30 AMRiverwalk AB
Posters/Exhibits/Break

P401
Analysis Of Pharmacist Interventions Within A Direct Oral Anticoagulation Management Protocol
Clara J Nickel2, Anne E Rose1
1University of Wisconsin Health , Madison, WI, United States, 2University of Wisconsin School of Pharmacy , Madison, WI, United States

P402
Characterization Of The Endothelial Cell Subpopulations Marked By Tek And Cdh5 Promoter Driven Cre Expression In Different Mouse Strains
David Svilar1,2, Audrey Cleuren1,3, David Siemieniak1, David Ginsburg1,2,4,5
1Life Sciences Institute, University of Michigan, Ann Arbor, MI, United States, 2Department of Pediatrics, University of Michigan, Ann Arbor, MI, United States, 3Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, United States, 4Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States, 5Department of Human Genetics, University of Michigan, Ann Arbor, MI, United States

P403
Electronic Medical Record Interventions In Reducing Inappropriate Testing For Heparin Induced Thrombocytopenia: Experience In A Large Teaching Hospital System
Mukul Singal1,2, Soon K. Low3,4, Peter A. Kouides5,6, Maura Wychowski6, Ronald L. Sham5,6
1Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, United States, 2Hematology and Oncology Fellowship, Rochester General Hospital, Rochester, NY, United States, 3Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY, United States, 4Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States, 5Mary M. Gooley Hemophilia and Thrombosis Center, Rochester, NY, United States, 6Department of Hematology and Oncology, Rochester General Hospital, Rochester, NY, United States

P404
Artificial Intelligence And Venous Thromboembolism: Talking To The Experts
Anuranita Gupta1, Barbara D Lam2,13, Sabrina Zerbey2, William Robertson3, Rachel P Rosovsky4, Leslie Lake5, Laura Dodge6, Alys Adamski7, Nimia Reyes7, Karon Abe7, Ioannis Vlachos8, Jeffrey I Zwicker9,10, Mara Schonberg11, Rushad Patell12
1Department of Medicine, Beth Israel Deaconess Medical Center, 2Division of Hematology, Department of Medicine, Beth Israel Deaconess Medical Center,, 3Weber State University, 4Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, 5National Blood Clot Alliance, 6Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 7Division of Blood Disorders and Public Health Genomics, Centers for Disease Control and Prevention, 8Department of Pathology, Cancer Research Institute, Beth Israel Deaconess Medical Center, 9Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 10Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 11Division of General Medicine, Beth Israel Deaconess Medical Center, 12Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, 13Division of Clinical Informatics, Beth Israel Deaconess Medical Center

P405
T-Hlper Cytokine Interactions With Baff In The Factor Viii Immune Response
Tammi L. Briscoe1, Mostafa A. Shaheen1, Bhavya S. Doshi1,2
1Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, United States, 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, United States

P406
Surgical And Procedural Outcomes For Patients With Factor Viii Deficiency Taking Emicizumab Prophylactically: A Regional Approach To Data Collection And Analysis
Janice Kuhn1, Butler Regina2, Mailie-Howell Lisa2, Druzgal Colleen3, Sennett Margy3
1Virginia Commonwealth University, Richmond, VA, United States, 2Children's Hospital of Philadelphia, Philadelphila, PA, United States, 3University of Virginia, Charlottesville, VA, United States

P407
Trends Of Acute Ischemic Stroke In Hereditary Hemorrhagic Telangiectasia: A Decade Study
Ayobami Olafimihan1, Stanley ozogbo2, Praise fawehinmi3, Gbolahan Olatunji4, Emmanuel Kokori4, Aderinto Nicholas5, Ekrem Turk1, Lina George1, Shaka Hafeez1
1John H. Stroger Jr Hospital , Chicago, IL, United States, 2Mercy Health- St. Elizabeth Hospital , Youngstown, OH, United States, 3Southern Illinois University Edwardsville, Chicago, IL, United States, 4University of Ilorin, Ilorin, Nigeria, 5Ladoke Akintola University of Technology, Ogbomosho, Nigeria

P408
Sustained Efficacy And Safety 3 Years Following Infusion With Etranacogene Dezaparvovec In Adults With Severe Or Moderately Severe Hemophilia B In The Phase 3 Hope-B Clinical Trial
Steven W. Pipe1, Paul van der Valk2, Peter Verhamme3, Peter Kampmann4, Frank Leebeek5, Michiel Coppens6, Nigel Key7, Nathan Visweshwar8, Guy Young9, Richard Lemons10, Robert Klamroth11, Niamh O'Connell12, Sandra le Quellec13, Paul Monahan13, Cedric Hermans14
1Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, United States, 2Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands, 3Center for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium, 4Rigshospitalet, Copenhagen, Denmark, 5Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands, 6Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, 7University of North Carolina, Chapel Hill, NC, United States, 8University of South Florida, Tampa, FL, United States, 9University of Southern California Keck School of Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, United States, 10University of Utah, Salt Lake City, UT, United States, 11Vivantes Klinikum im Friedrichshain, Berlin, Germany, 12National Coagulation Centre, St. James’s Hospital, Dublin, Ireland, 13CSL Behring, King of Prussia, PA, United States, 14Division of Haematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium

P409
Long-Term Safety And Efficacy Of Fitusiran Prophylaxis In A Phase 1/2 Open-Label Extension Study In People With Moderate Or Severe Hemophilia A Or B
Steven W. Pipe1, Toshko Lissitchkov2, Sarah Mangles3, Pencho Georgiev4, Erin Feng5, Laurel A. Menapace6, Salim Kichou7, Shauna Andersson6, Marek Demissie6, Margaret Ragni8
1University of Michigan, Ann Arbor, MI, United States, 2Clinic Specialized Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria, 3Haemophilia, Haemostasis and Thrombosis Centre, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom, 4University Multiprofile Hospital for Active Treatment , Plovdiv, Bulgaria, 5Sanofi, Shanghai, China, 6Sanofi, Cambridge, MA, United States, 7Sanofi, Paris, France, 8University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, United States

P410
Thromboelastometry (Teg): Utility In Diagnosing Of Infection In Neurosurgery Intensive Care Unit (Icu) As Compared To Established Biomarkers
Renu Rani, Deepak Agarwal
AIIMS, New Delhi, India

P411
Fourth Interim Analysis Of The Hem-Powr Study: Evaluating Real-World Effectiveness And Safety Of Damoctocog Alfa Pegol In Previously Treated Patients With Hemophilia A In The United States
Mark T Reding1, Beng Fuh2, Vanessa Salinas3, Maissaa Janbain4
1University of Minnesota Medical Center, Minneapolis, MN, United States, 2East Carolina University, Greenville, NC, United States, 3Center for Inherited Blood Disorders, Orange, CA, United States, 4Tulane School of Medicine, New Orleans, LA, United States

P412
Emicizumab Prophylaxis In People With Hemophilia A: Summary Of 10 Years Of Safety Data On Thromboembolic Events And Thrombotic Microangiopathy
Katayon Sarouei1, Simona Barlera2, Letizia Polito3, Guillermo Tobaruela3, Juliana M.L Biondo1
1Genentech, Inc., South San Francisco, CA, United States, 2Parexel International, Milan, Italy, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland

P413
Acquired Von Willebrand Syndrome In Monoclonal Gammopathy Of Undetermined Significance: A Focus On Response To Treatment With Ivig
Tanna Tan1, Rajiv K. K. Pruthi2, Aneel A. Ashrani2, Meera Sridharan2
1Division of Internal Medicine, Mayo Clinic, Rochester, MN, United States, 2Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, United States

P414
Title: Recombinant Adamts13 Replacement Therapy In A Pediatric Patient With Congenital Thrombotic Thrombocytopenic Purpura.
Katrina` Unpingco1, Michael F. Guerrera2, Zahara Jones1, Alison Matsunaga1
1Hemophilia and Thrombosis Center UCSF Benioff Children's Hospitals, Oakland -San Francisco, CA, United States, 2Hemostasis and Thrombosis Center, Children's National Medical Center, Washington , DC, United States

P415
Time To Stable Therapeutic Anticoagulation Using Weight-Based Iv Heparin Dosing Clinical Decisions Support Program
Keri S. Kim, Jean Lee, Miranda Hart, John Garofalo, Jeffrey J. Mucksavage
University of Illinois Chicago College of Pharmacy, Chicago, IL, United States

P416
Monitoring Bivalirudin Anticoagulant Effect By The Addition Of Diluted Thrombin Time Compared To Activated Partial Thromboplastin Time Alone
Vadim Kostousov, Karen Bruzdoski, Jun Teruya
Texas Children's Hospital, Baylor College of Medicine, Houston, TX, United States

P417
Comparative Protamine Sulfate And Hepa-Remove Neutralization Studies In Potency Adjusted Porcine And Bovine Heparin
Emily Krupa, Debra Hoppensteadt-Moorman, Walter Jeske, Jawed Fareed
Loyola University Medical Center, Maywood, IL, United States

P418
The Risk Of Recurrent Venous Thromboembolsim And Hemorrhage In The Postpartum Patient Requring Anticoagulation
Thomas Kiebalo1,2, Ann Malinowski1,4, Jose Carvalho1,5, Nadine Shehata1,2,3
1Mount Sinai Hospital, Toronto, ON, Canada, 2Department of Medicine, University of Toronto, Toronto, ON, Canada, 3Department of Hematology , University of Toronto, Toronto, ON, Canada, 4Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada, 5Department of Anesthesiology, University of Toronto, Toronto, ON, Canada

P419
Novel Thrombophilia- Prothrombin Belgrade Variant In A Mexican Family
Natalie/A Montanez1,3, Miguel/A Escobar1,2,3
1University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, United States, 2University of Texas Health Science Center of Houston, McGovern Medical School, Department of Internal Medicine, Houston, TX, United States, 3Gulf States Hemophilia and Thrombophilia Center , Houston, TX, United States

P420
&Ldquo;There Is So Much Power In Just Believing Someone&Rdquo;: Understanding The Lived Experiences Of Women With Heavy Vaginal Blood Loss
Fartoon M Siad1, Andrea Lausman2, Carolyn Snider3, Martina Trinkaus1, Filomena Meffe2, Michelle Sholzberg 1,4
1Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Department of Obstetrics and Gynecology, Toronto, ON, Canada, 3Division of Emergency Medicine, Toronto, ON, Canada, 44Department of Laboratory Medicine and Pathobiology, St. Michael’s Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, ON, Canada

10:30 - 11:30 AMSheraton Ballroom I-II
Short Talks - Bleeding Back to the Basics

Chair(s): Bobby Lee
10:30
Germinal Center And Non-Germinal Center B Cell Response To Factor Viii In Hemophilia A Patients
Maya Maarouf1, Ian Smith1, Wallace H Baldwin1, John F Healey1, Ernest T Parker1, Courtney Cox1, Robert F Sidonio, Jr1, Karen L Zimowski1, Glaivy Batsuli2, Bhavya S Doshi3, Shannon L Meeks1, Seema R Patel1
1Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta/Emory University School of Medicine, Atlanta, GA, United States, 2Stanford University, Palo Alto, CA, United States, 3Department of Pediatrics, Division of Hematology, Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA, United States

10:45
Enhanced Activation Of Fviii Positively Impacts Clot Formation In Vivo Using Hemophilia A Mice
Lacramioara Ivanciu1, 2, Mettine H.A. Bos1, Rodney M. Camire1, 2
1The Children's Hospital of Philadelphia, Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, United States, 2University of Pennsylvania, Department of Pediatrics, Philadelphia, PA, United States

11:00
Intrinsic Xase Ligand Interactions Impact Fviiia Regulation
John J Morris1,2, Nicole A Parsons2, Robert J Davidson1, Lindsey A George1,2
1Children's Hospital of Philadelphia, Philadelphia, PA, United States, 2University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States

11:15
Procoagulant Rescue Of Hemophilia B Causing Factor Ix Variants By Factor Fviii Mimetics
Kyumin Lee1,2, Yani Suber1,2, Julia Q. Chau1,2, Sebastian E. Leyes Porello1,2, Bhavya S. Doshi1,2, Ben J. Samelson-Jones1,2
1The Children’s Hospital of Philadelphia, Division of Hematology, Philadelphia, PA, United States, 2University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States

10:30 - 11:30 AMSheraton Ballroom IV-V
Short Talks - Taking Lab Monitoring to the Next Level

Chair(s): Kristi Smock
10:30
Factor Ii And X (Fiix) Monitored Warfarin Is More Effective Than Pt-Inr Monitored Warfarin And Direct Oral Anticoagulants In Patients Anticoagulated Long-Term For Non-Valvular Atrial Fibrillation. The Greater Reykjavik Oral Anticoagulation (Groac) Study.
Arnar B. Ingason1,2, Brynja R. Gudmundsdottir1, Ragnar Palsson1,3,4, Arnar S. Agustsson1, Edward Rumba1, Daniel A. Palsson1, Indridi Reynisson1, Sigrun H. Lund5, Johann P. Hreinsson6, Einar S. Bjornsson1,5, Pall T. Onundarson1,5
1Landspitali National University Hospital, Reykjavik, Iceland, 2University of Vermont, Burlington, VT, United States, 3Massachusetts General Hospital, Boston, MA, United States, 4Harvard University, Boston, MA, United States, 5University of Iceland, Reykjavik, Iceland, 6Sahlgrenska University, Gothenburg, Sweden

10:45
Drop-Of-Blood Coagulation Analysis By I-QattTm
Huy Q Pham1, Collette Barnor1, Daishen Luo1, Elizabeth M Cummins1, Nithya Kasireddy1, Daniel Arango2, Shaun Yockelson3, Damir B Khismatullin1
1Department of Biomedical Engineering, Tulane University, New Orleans, LA, United States, 2The University of Texas Medical Branch, Galveston, TX, United States, 3Department of Anesthesiology and Perioperative Medicine, Ochsner Medical Center, New Orleans, LA, United States

11:00
Real-World Use And Correlation Between Platelet-Dependant Activity Assays Of Von Willebrand Factor (Vwf):Ab And Vwf:Gp1Bm In Patients With Von Willebrand Disease In The Age Of The New Guidelines: A Single-Center Study
Prarthana Parthasarathy, Kerry M Hege
Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN, United States

11:15
Icoaglab Permits Comprehensive Coagulation Profiling In Patients On Percutaneous Cardiac Pump Support
Eli J Foster, Nathaniel Hai, Ziqian Zeng, Seemantini K Nadkarni
Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

10:30 - 11:30 AMChicago Ballroom VII
Short Talks - Industry Thrombosis - No CME

Chair(s): Vinai Bhagirath
10:30
Efficacy And Safety Is Maintained In Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan For Up To 3 Years
Carlos de Castro1, Brian Mulherin2,3, Christopher J. Patriquin4, Veena Selvaratnam5, Raymond Siu Ming Wong6, Richard J. Kelly7, Lisa Tan8,9, Peter Hillmen10, Dale Zhang10, Regis Peffault de Latour11,12
1Duke University, Durham, NC, United States, 2Hematology Oncology of Indiana, Indianapolis, IN, United States, 3Ascension St. Vincent Carmel, Carmel, IN, United States, 4University Health Network, Toronto, ON, Canada, 5Ampang Hospital, Ampang, Malaysia, 6The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong, 7Department of Haematology, St. James’s University Hospital, Leeds, United Kingdom, 8Swedish Orphan Biovitrum AB, Stockholm, Sweden, 9Lisa Tan Pharma Consulting Ltd., Cambridge, United Kingdom, 10Apellis Pharmaceuticals, Inc., Waltham, MA, United States, 11French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France, 12Université Paris Cité, Paris, France

10:45
Safety And Efficacy Of Long-Term Treatment Of Type 1 Plasminogen Deficiency Patients With Intravenous Plasminogen Replacement Therapy
Amy D Shapiro1, Heather McDaniel2, Robert W Decker3, Jeremy Lorber3, Karen Thibaudeau4, Joseph M Parker5
1Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, United States, 2Vanderbilt University, Nashville, TN, United States, 3Cedars Sinai Medical Center, Los Angeles, CA, United States, 4Kedrion, Laval, Canada, 5Kedrion, Fort Lee, NJ, United States

11:00
Tolerability And Pharmacodynamic Effect Of Regn9933, A Monoclonal Antibody Directed Against The Factor Xi Apple 2 Domain: Results From A First-In-Human Study
Ethan Marin1, Guixian Lin1, Hisham Abdallah1, David Gutstein1, Andrew Kordahi2, Karoline Meagher1, Frederic Cauwberghs3
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States, 2Regeneron Pharmaceuticals, Inc. (at time of study), Tarrytown, NY, United States, 3SGS (at time of study), Antwerp, Belgium

11:45
Safety And Efficacy Of Valoctocogene Roxaparvovec Gene Transfer For Severe Hemophilia A: An Update From 4 Years After Treatment
Andrew D Leavitt1, Johnny Mahlangu2, Emily Symington3, Doris V Quon4, Adam Giermasz5, Nigel S Key6, Steven W Pipe7, Bella Madan8, Sheng-Chieh Chou9, Robert Klamroth10,11, Jane Mason12, Flora Peyvandi13,14, Hua Yu15, Tara M Robinson15, Margareth C Ozelo16
1Adult Hemophilia Treatment Center, University of California San Francisco, San Francisco, CA, United States, 2Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and NHLS, Johannesburg, South Africa, 3Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, 4Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, United States, 5Hemophilia Treatment Center, University of California Davis, Sacramento, CA, United States, 6UNC Blood Research Center, University of North Carolina, Chapel Hill, NC, United States, 7Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, United States, 8Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 9Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 10Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Berlin, Germany, 11Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany, 12Queensland Haemophilia Centre, Cancer Care Services, Royal Brisbane and Women’s Hospital, Brisbane and University of Queensland, Brisbane, Australia, 13Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy, 14Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy, 15BioMarin Pharmaceutical Inc., Novato, CA, United States, 16Hemocentro UNICAMP, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil

11:45 - 12:45 PMChicago Ballroom VI
The Role of the Liver in Hemophilia Gene Therapy & Clinical Implications (Sponsored by Pfizer)

The advent of liver directed-gene therapies in hemophilia has placed increasing interest on liver health in the pre and post infusion settings. This session will explore the role of the liver in hemophilia gene therapy including evaluation of liver heath and key considerations for clinical management from a hepatologist�s perspective.


11:45 - 12:45 PMChicago Ballroom IX-X
VONVENDI Prophylaxis for Severe Type 3 von Willebrand Disease - Patient Case Discussion (Sponsored by Takeda Pharmaceuticals)

Join our expert HCP and a patient living with von Willebrand Disease (VWD) for an interactive journey. Our panel will guide you through the patient�s experience with VWD, review their treatment history, and discuss how VONVENDI may be added to the treatment plan for prophylaxis.


12:45 - 1:30 PMRiverwalk AB
Posters/Exhibits/Break

P502
Evaluation Of Anticoagulation Management In Patients With Suspected Heparin-Induced Thrombocytopenia Awaiting Diagnosis Confirmation
Alyssa R. George, Katelyn Sylvester, Dareen Kanaan, Delaney Corcoran, Kenneth Lupi, Brian Schuler, Jean M. Connors
Brigham and Women's Hospital, Boston, MA, United States

P503
Natural History Of Bleeding, Transfusion, And Antibody Prevalence In A Subset Of Hermansky-Pudlak Syndrome Patients: Effects Of Freeze-Dried Lyophilized Platelet Derived Hemostat Ex Vivo
Keith Moskowitz, Michael Fitzpatrick, Lisa Booth, Maria Abreau-Blanco, Matthew Dickerson, Anna Yu, Anya Derbij, W. Allan Alexander
Cellphire Therapeutics, Inc., Rockville, MD, United States

P504
Chimeric Antigen Receptor (Car) T Cell Treatment In Very High Titer Inhibitor Murine Model Requires Cd19 And Bcma Targeting
Julia Q. Chau2, Caroline Markmann1, Zheng Zhang1, Michael C. Milone1, Bhavya S. Doshi2,3, Vijay G. Bhoj1, Benjamin J. Samelson-Jones2,3
1Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, 2The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, United States, 3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

P505
Normalization Of Thrombin Generation Results Using Within-Run Plasma Normalizator Simultaneously.
Loic J. Letertre1,2, Pall T. Onundarson1, Jon T. Bergthorsson1,2
1Landspitali - The National University Hospital, Reykjavik, Iceland, 2The University of Iceland, Reykjavik, Iceland

P506
Two-Center External Validation Of A Machine Learning Natural Language Processing (Nlp) Algorithm For Venous Thromboembolism (Vte) Ascertainment
Shengling Ma1, Omid Jafari1, Arash Maghsoudi1, Jennifer La2, 3, Emily Zhou4, Iuliia Kovalenko5, Steven Horng3, 6, Nathanael Fillmore2, 3, Ang Li1, Barbara Lam6
1Baylor College of Medicine, Houston, TX, United States, 2VA Boston Healthcare System, Boston, MA, United States, 3Harvard Medical School, Boston, MA, United States, 4University of Texas Health Science Center at Houston, Houston, TX, United States, 5UPMC Harrisburg, Harrisburg, PA, United States, 6Beth Israel Deaconess Medical Center, Boston, MA, United States

P507
Child Hemo-Tem Observer-Reported Outcome Measure: Understanding And Assessing Treatment Burden In Children With Hemophilia
Meryl Brod1, Donald M. Bushnell2, Jesper Skov Neergaard3, Anne Kirstine Busk3, Vlady Ostrow4
1The Brod Group, Mill Valley, CA, United States, 2Evidera|PPD, Bethesda, MD, United States, 3Novo Nordisk A/S, Søborg, Denmark, 4Novo Nordisk Inc., Plainsboro, NJ, United States

P508
Long-Term Evaluation Of Liver Health In Participants Who Received Fidanacogene Elaparvovec: Data From A Phase 1/2A Study With Up To 6 Years Of Follow Up
Jonathan Ducore1, Lindsey A George2, Ben J Samelson-Jones2, John Rasko3, Catherine McGuinn4, Adam Giermasz1, Jerome Teitel5, Katherine High6, Jeremy Rupon7, Annie Fang7, Lynne Smith7, Priya Patel7, Amit Chhabra7, Frank Plonski7, Matko Kalac7
1UC David Comprehensive Cancer Center, Sacramento, CA, United States, 2Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 3Centenary Institute, Sydney, Australia, 4Weill Cornell Medical Center, New York, NY, United States, 5University of Toronto, Toronto, ON, Canada, 6University of Pennsylvania, Philadelphia, PA, United States, 7Pfizer Inc, New York, NY, United States

P509
Emicizumab For Severe Von Willebrand Disease (Vwd) And Vwd/Hemophilia A: The Emivwd Study
Jonathan Roberts1,2, MIchael Tarantino1,2
1Bleeding & Clotting Disorders Institute, Peoria, IL, United States, 2Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, United States

P510
Design Of A Prospective, Observational, Multicenter Study Of The Effectiveness Of Efanesoctocog Alfa On Long-Term Joint Health In Patients With Hemophilia A In The United States And Japan
Jonathan C. Roberts1, Spencer Sullivan2, Eric F. Grabowski3, Doris Quon4, Jennifer Dumont5, Annemieke Willemze6, Nicole Tsao5
1Bleeding & Clotting Disorders Institute, Peoria, IL, United States, 2Mississippi Center for Advanced Medicine, Madison, MS, United States, 3Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States, 4Orthopedic Hemophilia Treatment Center, Los Angeles, CA, United States, 5Sanofi, Cambridge, MA, United States, 6Sanofi, Amsterdam, Netherlands

P511
Seroprevalence And Seroconversion Among People With Hemophilia A In The United States: Observations From The Saavy (Seroprevalence Of Aav Antibody) Study
Amy Shapiro1, Leonard A. Valentino2,3, David Hinds4, Manil Vaghela5, Erin Goodman4, Karim Iskander4, George Dela Cerda 4, Kim Schafer6, Steven Pipe7
1Indiana Hemophilia Thrombosis Center, Indianapolis, IN, United States, 2National Bleeding Disorders Foundation, New York, NY, United States, 3Rush University, Chicago, IL, United States, 4BioMarin Pharmaceutical, Novato, CA, United States, 5BioMarin Pharmaceutical, London, United Kingdom, 6Hemostasis and Thrombosis Center, UC Davis Health, Sacramento, CA, United States, 7Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, United States

P512
Real-World Data On Emicizumab Prophylaxis In Older Persons With Hemophilia A: A Retrospective Single Center Cohort Study
Shalini Vemuru1, Stacey Fedewa2,3, Christine Kempton2,3
1Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, United States, 2Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States, 3Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, United States

P513
Clinical Utility And Performance Of Von Willebrand Factor Activity Assays In A National Reference Laboratory: The Vitalant Coagulation Laboratory&Rsquo;S Experience With The Ristocetin Cofactor And Vwf:Gp1Bm Assays
Angela Verdoni1, Mason Marshall2, Irina Chibisov1
1Vitalant Coagulation Laboratory, Pittsburgh, PA, United States, 2Department of Pathology, University of Pittsburgh, Pittsburgh, PA, United States

P514
Brain Volumes And Neurocognitive Outcomes In Children With Hemophilia A
Silvia Verhofste1, Ahmad Al-Huniti1, 2, Marci Novak1, Amy L. Conrad1, 5, 6, Ellen van der Plas3, 4, Lyndsay Harshman1, 5, 6, Janice M. Staber1, 5, 6
1Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA, United States, 2*Current Location - Mayo Clinic , Rochester, MN, United States, 3Department of Psychiatry, University of Iowa, Iowa City, IA, United States, 4*Current Location -University of Arkansas for Medical Sciences, Pediatrics Arkansas Children's Hospital, Hematology/Oncology, Little Rock, AR, United States, 5The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, IA, United States, 6Iowa Neuroscience Institute, Iowa City, IA, United States

P515
Single Center Retrospective Comparison Of Bivalirudin And Heparin For Therapeutic Anticoagulation In Pediatric Patients
Clayton Habiger, Shannon Carpenter
Children's Mercy Hospital, Kansas City, MO, United States

P516
Transitioning From Oral Factor Xa Inhibitor To Unfractionated Heparin Using Heparin-Calibrated Anti-Xa Levels
Mahnoor M Khan1, Magdalena E Jasinska2, Jeremy P Kosacz3, Erin N Robinson1, Lisa M Thompson3, Brandon Pierce3, Anne E Rose1
1UW Health - Madison, Madison, WI, United States, 2University of Wisconsin School of Pharmacy , Madison, WI, United States, 3UW Health - Northern Illinois , Rockford, IL, United States

P517
Covid-19 Venous Thromboembolism Prophylaxis Guidelines
Sara McElroy1,2, Emily Cramer1,2, Lauren Amos1,2
1Children's Mercy Kansas City, Kansas City, MO, United States, 2University of Missouri-Kansas City, Kansas City, MO, United States

P518
Benefit Of Albumin Infusion In An Elderly Cirrhotic Patient On Doac: About A Case .
LAMIA AIT OUALI1, FARID SLIMANI2, SAMIA OULARBI1, SAMIR TINE1,3
1APHP René Muret , Sevran, France, 2APHP Jean Verdier , Bondy, France, 3APHP Avicenne, Bobigny, France

P519
The Severe Von Willebrand Disease Patient Registry: A Longitudinal Natural History And Patient Outcomes Study
Johnna Cesta1, Mrinal Gounder1, Christopher Walsh 2, Alice Araphsian1, Jeanette Cesta1, Christina Morgenthaler1
1VWD Connect Foundation , Wellington , FL, United States, 2Icahn School of Medicine Mount Sinai Hospital, New York , NY, United States

P520
Effect Of Doac Stop On Coagulation Factor Activity Levels
Dan A Stephens1, Ronda A Crist1, Karen A Moser1, Allison Carey1,2, Abdulrahman Saadalla1,2, Kristi J Smock1,2
1ARUP Laboratories Institute for Clinical and Experimental Pathology, Salt Lake City, UT, United States, 2University of Utah Department of Pathology

1:30 - 2:45 PMSheraton Ballroom IV-V
Abortion/Reproductive Health - When the law and healthcare collide - How laws that restrict access to reproductive care are affecting hemostasis and thrombosis patients

Chair(s): Julie Jaffray
1:30
Effect On Stem Cell Research
Paul Blumenthal

1:55
Post-Roe&Rsquo;S Downstream Effects - Impacting Patients, Personnel & Trainees
Alyssa Colwill

2:20
Impact On Clinical Care Thrombosis And Hemostasis
Jeff Federspiel

3:00 - 4:30 PMSheraton Ballroom I-II
Ouch! Pain and Bleeding Disorders

Chair(s): Bethany Samuelson Bannow
3:00
Biopsychosocial Pain Mechanisms
Kalpna Gupta

3:30
Interdisciplinary Pain Assessment
Tyler Buckner

4:00
Barriers And Successes To Implementing Interdisciplinary Multimodal Pain Management
Lena Volland

3:00 - 4:30 PMSheraton Ballroom IV-V
Clinical Challenges for Antithrombotic Management in the Ambulatory Care setting

Chair(s): Anne Rose
3:00
De-Escalating Antithrombotic Therapy: How Do We Ensure Appropriate Use
Cynthia Fenton

3:30
Perioperative Considerations For Anticoagulation With Mechanical Devices And Heart Valves
James Douketis

4:00
Keeping Anticoagulation Clinics Relevant In The Next Decade
Kelly Rudd

3:00 - 4:30 PMChicago Ballroom VII
Immunothrombotic Syndromes

Chair(s): Cathy Hayward
3:00
Machine Learning For Hit
Adam Cuker

3:30
Immunothrombosis And Septicemia
Alison Fox-Robichaud

4:00
Complement Activation By Hit Immune Complexes
Sanjay Khandelwal

4:30 - 5:15 PMRiverwalk AB
Posters/Exhibits/Break

P601
Il-6-Induced Potentiation Of Platelet Activity And Glycosylation In Venous Thromboembolism
Michelle K. Brenner1, Karin Hoffmeister2, Brian Branchford1
1Pediatric Hematology/Oncology/Bone Marrow Transplant, Children’s Wisconsin and Medical College of Wisconsin, Milwaukee, WI, United States, 2Translational Glycomics Center, Versiti Blood Research Institute, Milwaukee, WI, United States

P602
Platelet-Nucleic Acid Receptor Promotes Pulmonary Thrombo-Inflammation In Sickle Cell Disease
Rikesh K. Dubey1, Omika Katoch1, Prithu Sundd1,2
1Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI, United States, 2Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States

P603
Athn Transcends: Natural History Cohort Study Of Bleeding Symptoms And Treatment Outcomes In Patients With Glanzmann Thrombasthenia
Divyaswathi Citla Sridhar1, Sanjay Ahuja2, Tammuella Chrisentery-Singleton3, Carrie O'Neil3, Catherine Rea4, Jigar Amin4, Mike Recht5,6, Meera Chitlur7
1Arkansas Children’s Hospital, University of Arkansas for Medical Sciences, Little Rock, AR, United States, 2Rainbow Babies & Children’s Hospital, Case Western Reserve University, Cleveland , OH, United States, 3American Thrombosis and Hemostasis Network, Rochester, NY, United States, 4Hemab Therapeutics, Cambridge, MA, United States, 5National Bleeding Disorders Foundation, New York, NY, United States, 6Yale University School of Medicine, New Haven, CT, United States, 7Central Michigan University/Children’s Hospital of Michigan, Detroit, MI, United States

P604
Anti-GpibΑ Antibodies In Fnait Are Associated With Recurrent Miscarriages
Christopher J. Khoury1-3, Pingguo Chen1-4, Guangheng Zhu2,3, Zoya Tawhidi1-3, Alan H. Lazarus1-4,8, Yiming Wang5, Karen Chong6, David Chitayat1,6, Heyu Ni1-4,7,8
1Department of Laboratory Medicine and Pathobiology, University of Toronto., Toronto, ON, Canada, 2Keenan Research Centre for Biomedical Science of St. Michael’s Hospital, Toronto, ON, Canada, 3Toronto Platelet Immunology Group, Toronto, ON, Canada, 4Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, 5Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto., Toronto, ON, Canada, 6The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 7Department of Physiology, University of Toronto, Toronto, ON, Canada, 8Department of Medicine, University of Toronto, Toronto, ON, Canada

P605
Utility Of Thromboelastography With Platelet Mapping (Teg-Pm) For Monitoring Platelet Transfusion In Qualitative Platelet Disorders
Robert H. Lee1,2, Tanvi Rudran2, Wolfgang Bergmeier1,2
1Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

P606
Title: Real-World Efficacy Data On Adolescent Hemophilia A Patients Transitioning To Bay 81-8973 Or Bay 94-9027 In The Athndataset
Michael Recht1, Jessica Charlet2, Thomas Moulton2, Michael Recht3,4
1American Thrombosis & Hemostasis, NetworkRochester, NY, United States, 2Bayer Pharmaceuticals, USA, Whippany, NJ, United States, 3National Bleeding Disorders Foundation, New York City, NY, United States, 4Yale University School of Medicine, New Haven, CT, United States

P607
Burden Of Disease And Impact On Quality Of Life In Hereditary Factor X Deficiency Patients Who Were Diagnosed At Birth: Findings From The Hereditary Factor X Deficiency In America Survey
Kim Clark1, Amy Wu2, Denise A. Garner2, Lorie Mody2, Jaymin Patel2, Brian Branchford3
1Kedrion Biopharma, INC., Fort Lee, NJ, United States, 2AESARA, INC., Chapel Hill, NC, United States, 3Versiti Blood Research Institute, Medical College of Wisconsin, and Children's Wisconsin, Milwaukee, WI, United States

P608
Rebleed Incidence With Eptacog Beta Treatment Through 24 And 48 Hours In Children (Under 12 Years) With Hemophilia A Or B With Inhibitors
Amy L. Dunn1, Manuel Carcao2, Meera Chitlur3, Joanna Davis4, Nina Hwang5, Craig Kessler6, Catherine McGuinn7, Danielle Nance8, Robert Sidonio Jr.9, Tammuella Chrisentery-Singleton10, Courtney D. Thornburg11,12, Michael Wang13, Steven Pipe14
1Nationwide Children’s Hospital and The Ohio State University College of Medicine, Columbus, OH, United States, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Central Michigan University College of Medicine/Children’s Hospital of Michigan, Carmen and Ann Adams Department of Pediatrics, Division of Hematology/Oncology, Detroit, MI, United States, 4Pediatric Hemophilia Treatment Center, University of Miami, Miami, FL, United States, 5Center for Inherited Blood Disorders, Orange, CA, United States, 6Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States, 7Department of Pediatrics, Division of Pediatric Hematology/Oncology, Weill Cornell Medicine, New York, NY, United States, 8Banner MD Anderson Cancer Center, Gilbert, AZ, United States, 9Aflac Cancer and Blood Disorders Center and Emory University, Atlanta, GA, United States, 10American Thrombosis and Hemostasis Network, Rochester, NY, United States, 11Hemophilia and Thrombosis Treatment Center, Rady Children's Hospital-San Diego, San Diego, CA, United States, 12Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, United States, 13Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO, United States, 14University of Michigan, Ann Arbor, MI, United States

P609
Recurrent Pregnancy Loss In Type 3 Von Willebrand Disease With A Unique Mutation Profile
Amanda D. Kaveney, Claire Philipp
Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, United States

P610
Value Of Functional Protein S Activity Assays For Detection Of Type Ii Protein S Deficiency
Katharine A. Marsden, Shelbey Bauman, Peter F. Mannion, Morayma Reyes Gil
Cleveland Clinic Foundation, Cleveland, OH, United States

P611
Validating The Jakpot Prediction Rule For Identifying Which Patients With Erythrocytosis Are Unlikely To Have A Jak2 Mutation
Kevin O'Sullivan1, Roosevelt Lu1, Jason A Freed1, George Goshua2, Justine Ryu2, Rushad Patell1, Barbara D Lam1
1Beth Israel Deaconess Medical Center, Boston, MA, United States, 2Yale Medical Center, New Haven, CT, United States

P612
Clinical Outcomes In Mild-Moderate And Severe Patients With Hemophilia B: Results From A Real-World, Multi-National Survey
Sheena Thakkar1, Lisa Wilcox1, Valeria Merla1, Anna Kane1, Jose Alvir1, Surya Pemmaraju1, Jennifer Mellor2, Ella Morton2, Jade Garratt Wheeldon2, James Pike2, Nathan Ball2, Stevie Olsen2
1Pfizer Inc, New York, NY, United States, 2Adelphi Real World, Bollington, United Kingdom

P613
Outcomes In North American Participants Who Received Efanesoctocog Alfa Prophylaxis In The Xtend-1 Study
Annette von Drygalski1, Tung Wynn2, Doris Quon3, Anthony KC Chan4, Angela C Weyand5, Davide Matino6, Jennifer Dumont7, Andrew Wilson7, Umer Khan8, Sriya Gunawardena9
1Division of Hematology/Oncology, Department of Medicine, University of California San Diego, San Diego, CA, United States, 2Department of Pediatrics, University of Florida, Gainesville, FL, United States, 3Luskin Orthopaedic Institute for Children, Los Angeles, CA, United States, 4Department of Pediatrics, McMaster Children’s Hospital, McMaster University, Hamilton, ON, Canada, 5Division of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, United States, 6Division of Hematology & Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON, Canada, 7Sanofi, Cambridge, MA, United States, 8Sanofi, San Diego, CA, United States, 9Sanofi, Bridgewater, NJ, United States

P614
Health-Related Quality Of Life And Treatment Burden In Patients With Hemophilia A/B Without Inhibitors On Concizumab Prophylaxis: Results From The Phase 3 Explorer8 Study
Guy Young1, Gary Benson2, Hermann Eichler3, Johnny Mahlangu4, Jesper Skov Neergaard5, Jan Odgaard-Jensen5, Jay Jay Thaung Zaw5, Jameela Sathar6, Huyen Tran7, Tadashi Matsushita8, Emily K. Waters9
1Hemostasis and Thrombosis Center, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, 2Department of Hematology, Belfast Health and Social Care Trust, Belfast, Ireland, 3Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg, Saar, Germany, 4Department of Molecular Medicine and Haematology, School of Pathology, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa, 5Novo Nordisk A/S, Søborg, Denmark, 6Department of Haematology, Ampang Hospital, Selangor, Malaysia, 7Ronald Sawers Haemophilia Treatment Centre, Monash University, Melbourne, Australia, 8Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan, 9Novo Nordisk Inc., Plainsboro, NJ, United States

P615
Anticoagulant Management Of Cancer-Associated Thrombosis And Thrombocytopenia: A Retrospective Chart Review
Umaima Abbas1, Ushra Khan1, Robin Mackenzie1, Rija Fatima2, Tzu-Fei Wang3, Caroline Hamm1,4,5, Andrea Cervi1,4,5
1Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, 2Department of Translational Health Science, University of Windsor, Windsor, ON, Canada, 3Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada, 4Department of Biomedical Sciences, University of Windsor, Windsor, ON, Canada, 5Windsor Regional Hospital, Windsor, ON, Canada

P616
A Survey Of Clinician Practice Patterns On The Use Of Inferior Vena Cava Filters For Venous Thromboembolism
Jillian Calandra1, Rahman Ladak2, Massimo Sementilli3, Alejandro Lazo-Langner2,4, Deborah Siegal5,6, Tzu-Fei Wang5,6, Rong Luo7, Andrea Cervi7
1WE-SPARK Health Institute, Windsor, ON, Canada, 2Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, 3Department of Biomedical Sciences, University of Windsor, Windsor, ON, Canada, 4Lawson Health Research Institute, London, ON, Canada, 5Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada, 6Ottawa Hospital Research Institute, Ottawa, ON, Canada, 7Windsor Regional Hospital, Windsor, ON, Canada

P617
Inr Above Five Warfarin Events Inpatient Require Focus On Preventable Cases To Lower Incidence
Benjamin/J Jung1, Lisa Baumann-Kreuziger1,2, Garret Newkirk1
1Froedtert and Medical College of Wisconsin, MIlwaukee, WI, United States, 2Versiti Blood Center of Wisconsin, Milwaukee, WI, United States

P618
Evaluation Of Nurse-Managed Heparin Nomogram Adherence After Implementation Of An Electronic Medical Record-Embedded Heparin Calculator
Taylor Robichaux1, John Lindsley1, Vi Gilmore1, Rosemary Duncan1, Catherine Kiruthi1, Erica Willits2, Michael Streiff3, Rakhi Naik3, Jennifer Yui3, Kathryn Dane1
1Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, United States, 2Department of Nursing, The Johns Hopkins Hospital, Baltimore, MD, United States, 3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States

P619
A Comparison Of Targeted High-Range Versus Low-Range Anti-Xa Goal For Intravenous Unfractionated Heparin In Patients With Mechanical Circulatory Support Devices
Yue Wang, Long To, Mathew Jones, Kristin Griebe
Henry Ford Hospital, Detroit, MI, United States

5:15 - 6:45 PMSheraton Ballroom I-II
Anticoagulation for patients with bleeding related conditions

Chair(s): Vinai Bhagirath
5:15
Anticoagulants In Patients With Bleeding Disorders
Bethany Samuelson Bannow

5:45
Describing The Risks For Bleeding And Thrombosis Unique To Patients With Renal Impairment
William Dager

6:15
Resumption Of Anticoagulation Post Bleeding Event
Dan Witt

5:15 - 6:45 PMSheraton Ballroom IV-V
Cutting to the chase- Fibrinolysis

Chair(s): Jordan Shavit
5:15
Engineering Devices To Measure And/Or Enhance Fibrinolysis
Dante Disharoon

5:45
Tfpi As A Modifier Of Fibrinolysis And Bleeding In Fxi Deficiency
Stephanie Reitsma

6:15
Intersection Of Fibrin(Olysis) And Inflammation At The Oral Mucosa Barrier
Lakmali Silva

5:15 - 6:45 PMChicago Ballroom VII
Dissolving the Clot of Thrombilia Testing: Current Diagnostic Updates and Challenges

Chair(s): Karen Moser
5:15
Updates On Protein C And Protein S Deficiency Testing (Highlights And Critiques Of Recent Isth Documents)
Marian Rollins-Raval

5:45
Challenges In Practical Application Of La Testing Guidelines In North America: Mixing Studies And Beyond!
Jacqueline Poston, Andrew Goodwin

6:15
Pitfalls And Considerations For Thrombophilia Testing--How Can Laboratories Support Patients? (Purpura Fulminans, Acute Dic, Apas, Interferences Etc.)
Donna Castellone

7:00 - 8:00 PMChicago Ballroom VI
Elevating Hemophilia Care Beyond Bleed Management: A Multidisciplinary Panel Dialogue to Bridge Gaps in Patient Care (Sponsored by Sanofi)

Please join us for our panel of healthcare providers and patients/caregivers for a discussion on current unmet needs in hemophilia centered around findings from a Hemophilia Life Stages and Changes Global Survey of >2,700 patients, caregivers, and hematologists. As treatment options evolve, so must expectations and goals on management of hemophilia. This symposium will explore how communication gaps between HCPs and patients can improve to achieve positive change and better quality of life.


7:00 - 8:00 PMChicago Ballroom IX-X
Ask the Experts: Navigating Gene Therapy for Hemophilia - Lived Experience Perspectives from Patients and Providers (Sponsored by BioMarin)

Join us for dinner and hear from a panel of health care providers with hemophilia gene therapy experience (clinical trial and post-FDA approval), as well as patients with years of post-treatment experience. Panelists will review clinical trial data and discuss patient treatment outcomes and expectations. Have your questions answered by the panel and learn how gene therapy can be implemented in your Hemophilia Treatment Center.




Saturday, April 6, 2024


6:30 - 1:00 PMChicago Promenade
Registration

7:00 - 8:00 AMChicago Ballroom VI
Finding the Trusted Factor: 10 Years of FIX Experience Across Ages and Settings (Sponsored by Sanofi)

This presentation highlights a decade of experience (since FDA approval) with a Factor IX therapy, exploring its impact across various age groups and settings. You will hear from clinical experts and a patient as they share insights and experience with an EHL FIX therapy that has been trusted for 10 years.


7:00 - 8:00 AMChicago Ballroom IX-X
Paradigm Shifts in Hemophilia Prophylaxis: Putting Evidence Into Practice (Sponsored by Clinical Care Options, LLC)

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits�. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


8:15 - 9:45 AMSheraton Ballroom I-II
Bleeding in Hypermobility/Ehlers Danlos

Chair(s): Bobby Lee
8:15
Assessment And Management Of Bleeding In Pediatric Patients With Hypermobility Syndrome
Nicole Kendel

8:45
Pregnancy Complications And Outcomes In Ehlers Danlos Syndrome
Ashley Benson

9:15
Contribution Of Platelet Dysfunction To Bleeding In Ehlers Danlos Syndrome
Mariia Kumskova

8:15 - 9:45 AMSheraton Ballroom IV-V
Young, Wild and VTE - Treatment Considerations for Adolescents and Young Adults

Chair(s): Julie Jaffray
8:15
Pulmonary Embolus In Adolescents: Treatment Challenges And Opportunities
Julie Jaffray

8:45
Continuing "The Pill" Or Not?: Vte Treatment And Exogenous Hormones
Marie-Claude Pelland Marcotte

9:15
The Changing Landscape Of Anticoagulation Treatment In Children
Laura Avila

8:15 - 9:45 AMChicago Ballroom VII
Quality Improvement Efforts in Laboratory Hemostasis/Thrombosis Testing

Chair(s): Marian Rollins-Raval
8:15
Preanalytic Variables -- (Updates Including Clsi)
Annie Winkle

8:45
Factor Xiii Testing- What Is Available? What Are Best Practices For Testing? Effect Of Concentrates On Lab Tests? Antigen Versus Activity Testing? Any Remaining Role For Clot Solubility?
Natalie Mathews

9:15
Platelet Aggregation Testing In Thrombocytopenic Patients
Cathy Hayward

9:45 - 10:30 AMRiverwalk AB
Posters/Exhibits/Break

P701
Necessity Of Anti-Xa Level Monitoring For Prophylactic Enoxaparin In Children And Adolescents: A Single Institution Experience
Rene Gonzalez1, Abigail Davison1,2, Sarah E. Sartain1,2, Clay T. Cohen1,2
1Texas Children's Hospital, Houston, TX, United States, 2Baylor College of Medicine, Houston, TX, United States

P703
Insight Into Athn 16: Treatment Of Bleeding Events In Patients With Congenital Hemophilia A Or B With Inhibitors To Evaluate The Safety Of Coagulation Factor Viia (Recombinant)-Jncw
Tammuella Chrisentery-Singleton1, SUCHITRA ACHARYA2, SANJAY AHUJA3, LAUREN AMOS4, MEERA CHITLUR5, MIGUEL ESCOBAR6, ASHLEY EASON7, SHVETA GUPTA8, PHILLIP KURIAKOSE9, SHARON PENNINGTON10, RAJIV PRUTHI11, MICHAEL RECHT12, SPENCER SULLIVAN13, DORIS QUON14, ALLISON WHEELER15, MARK REDING16
1American Thrombosis and Hemostasis Network, Rochester, NY, United States, 2Northwell Health Hemostasis and Thrombosis Center, New Hyde Park, NY, United States, 3University Hospitals Health System Cleveland, Cleveland, OH, United States, 4Children’s Mercy Kansas City, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States, 5Central Michigan University/Children’s Hospital of Michigan, Detroit, MI, United States, 6University of Texas Health Science Center, Houston, TX, United States, 7Willett Children's Hemophilia Treatment Center at Memorial Health, Savannah, GA, United States, 8Arnold Palmer Hospital for Children, Orlando, FL, United States, 9Henry Ford Health System, Detroit, MI, United States, 10Louisiana Center for Advanced Medicine, Slidell, LA, United States, 11Mayo Clinic, Rochester, MN, United States, 12National Blood Disorders Foundation, New York, NY, United States, 13Mississippi Center for Advanced Medicine, Madison, MS, United States, 14Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, United States, 15Vanderbilt University Medical Center, Nashville, TN, United States, 16University of Minnesota Medical Center, Minneapolis, MN, United States

P704
Impact Of Mrna Covid-19 Vaccination On D-Dimer Levels And Anti-Pf4 Seroconversion In Healthy Adults: A Systematic Review
Evan Y Maroun M.S., Megan Centrella, Grace Hansen, Trevor Forsberg, Tariq Rahaman M.L.I.S., Hoang Nguyen M.D. Ph.D.
Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL, United States

P705
Utility Of Thromboelastography Versus Routine Coagulation Tests: Cardiac Bypass Surgery.
ISABEL RODRIGUEZ MARTIN
Hospital Universitario Virgen del Rocio, SEVILLA, Spain

P706
Clinical Outcomes Of Congenital Thrombotic Thrombocytopenic Purpura With And Without Prophylaxis Therapy: A Multinational Chart Review Study
Paul Coppo1, Marie Scully2, Johanna A Kremer Hovinga3, Maria Jose Aragon4, Parth Patwari5, Linda T Wang5, Björn Mellgård5, Ragy Saad5
1APHP.6–Reference Center for Thrombotic Microangiopathies (CNR-MAT), Hôpital St Antoine, Paris, France, 2University College London Hospitals NHS Foundation Trust, London, United Kingdom, 3Department of Hematology and Central Hematology Laboratory, Bern University Hospital, Bern, Switzerland, 4HCD Economics, Knutsford, United Kingdom, 5Takeda Development Center Americas, Inc., Cambridge, MA, United States

P707
The Impact Of Multidisciplinary Perinatal Care For Women With Bleeding Disorders
Vanessa Giuliano1, Natalya E. O’Neill1, Shamshah Aratia7, Shalene Wong7, Allison Rupnaraine,7, Rebecca Sampat7, Filomena Meffe2,3, Jeffrey Wassermann8, Jillian M. Baker4-6, Grace Tang7, Michelle Sholzberg1,7,9,10
1Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada, 3Department of Obstetrics and Gynecology, St. Michael’s Hospital, Toronto, ON, Canada, 4Department of Pediatrics, St. Michael’s Hospital, Toronto, ON, Canada, 5Department of Paediatrics, Division of Haematology-Oncology, The Hospital for Sick Children, Toronto, ON, Canada, 6Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 7St. Michael's Hospital, University of Toronto, Toronto, ON, Canada, 8Department Of Anaesthesia, University of Toronto, Toronto, ON, Canada, 9Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 10Li Ka Shing Knowledge Institute, Toronto, ON, Canada

P708
Temporal Trends And Predictors Of Venous Thromboembolism In Hospitalized Chronic Lymphocytic Leukemia Patients
Michael Imeh1, Ani Gvajaia1, Chukwunonye Amaeshi2, Fidelis Uwumiro3
1Lincoln Medical and Mental Health Centre, Bronx, NY, United States, 2Montefiore Medical Centre, Bronx, NY, United States, 3University of Benin Teaching Hospital , Benin, Nigeria

P709
Deep Phenotyping Reveals A High Prevalence Of Distressing Bleeding Symptoms In Patients With Hypermobile Ehlers Danlos Syndrome (Heds) Spectrum Disease .
Rohith Jesudas1, Sarah Mathena 2, Kenneth L. Zhang3, Christina Laukaitis3,4, Jennifer Andrews2
1St. Jude Children’s Research Hospital, Memphis, TN, United States, 2University of Arizona, Tucson, AZ, United States, 3Carle Illinois College of Medicine, Urbana, IL, United States, 4Carle Foundation Hospital, Urbana, IL, United States

P710
Indirect Comparison Of Prophylaxis Efficacy Between Simoctocog Alfa And Efanesoctocog Alfa In Severe Hemophilia A And Their Cost In The United States
Craig M. Kessler1, Fernando F. Corrales-Medina2
1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, DC, United States, 2University of Miami-Miller School of Medicine, and University of Miami-Hemophilia Treatment Center, Miami, FL, United States

P711
Risk Of Thrombosis In Sglt2 Inhibitor-Associated Erythrocytosis: A Multi-Center Propensity-Matched Analysis
Meric Mericliler1,2
1Division of Hematology and Medical Oncology, Virginia Commonwealth University Health, Richmond, VA, United States, 2Massey Cancer Center, Richmond, VA, United States

P712
Hospitalization Outcomes From Venous Thromboembolism In Cancer Patients: An Analysis Of The National Inpatient Sample Data From 2016 To 2019
Youjin oh, Alejandro Vallejo, Alexandra Sueldo, Lina james, Angelo Caputi Zuniga, Ayobami Olafimihan, Ekrem Turk
John H. Stroger Jr Hospital , Chicago, IL, United States

P713
Accurate Measurement Of Factor Viii Activity And Inhibitors In The Presence Of Mim8
William Pickering1, Karin Nana Weldingh2, Mary Robinson1, Caroline Cogswell1, Wan Hui Ong Clausen2, Mirella Ezban2, Vlady Ostrow3
1Labcorp Colorado Coagulation, Englewood, CO, United States, 2Novo Nordisk A/S, Søborg, Denmark, 3Novo Nordisk Inc., Plainsboro, NJ, United States

P714
First Real-World Experience Administering Etranacogene Dezaparvovec Gene Therapy For People With Hemophilia B
Matthew Ryan1, Andrea B. Miller1, Patrick O'Hearn1, Vidhi Desai2, Nathan Visweshwar3
1Hemophilia Outreach Center, Green Bay, WI, United States, 2CSL Behring, King of Prussia, PA, United States, 3University of South Florida, Tampa, FL, United States

P715
Thrombosis Rates And Use Of Thromboprophylaxis After Discharge From Gynecologic Cancer-Related Surgery
Leticia Campoverde, Alyssa Mercadel, Dan Morgenster, Asaad Trabolsi, Thomas Plate IV, Rachel Kronenfeld, Wei Zhao, Matthew Schlumbrecht , Gerald Soff
University of Miami, Miami, FL, United States

P716
Incidence Of Gastrointestinal Bleeding In High-Risk Cardiovascular Patients Taking Antithrombotic Medications With Proton Pump Inhibitors
Mark Edwards1, Xiaowen Kong1, Jacob Kurlander1, Scott Kaatz2, James B Froehlich1, Twylla Tassava3, Christopher Giuliano4, Geoffrey D Barnes1
1University of Michigan-Michigan Medicine, Ann Arbor, MI, United States, 2Henry Ford Health- Division of Hospital Medicine, Detroit, MI, United States, 3Trinity Health-Ann Arbor, Ann Arbor, MI, United States, 4Ascension- St. John Hospital, Detroit, MI, United States

P717
Accuracy Of A Warfarin Clinical Dosing Algorithm Enriched With Genetic Information Compared To The Use Of Clinical Algorithm
Amr Fahmi1, Ahmed El Bardissy1, Mohamed Saad1, Mohamed Nabil1, Loulia Bader2, Mohamed Kassem1, Ahmed Mahfouz1, Hazem Elewa2
1Hamad Medical Corporation, Doha, Qatar, 2College of Pharmacy, QU Health, Qatar University, Doha, Qatar

P718
Safety And Cost-Effectiveness Analysis Of Anticoagulation Therapy In Adult Patients Undergoing Extracorporeal Membrane Oxygenation
Amanda Arenella1, Michael Calloway1, Joshua Oh2
1Department of Health Economics and Outcomes Research, Grifols SSNA, Research Triangle Park, NC, United States, 2University of North Carolina at Charlotte, College of Health and Human Services, Department of Public Health Sciences , Charlotte, NC, United States

P719
What Is The Role Of Family History In The Management Of Vte?
Ayan Ramanathan1, Ishan Dhaneshwar1, Joseph Caprini3, Fakiha Siddiqui2, Atul Laddu1, Jawed Fareed2, Krish Punyarthi1, Richa Mahajan1
1Global Thrombosis Forum , Suwanee , GA, United States, 2Loyola University , Chicago, IL, United States, 3Northshore University Health System , Evanston, IL, United States

10:30 - 11:30 AMSheraton Ballroom I-II
Short Talks - Bleeding: Outcomes and Predictors

Chair(s): Bethany Samuelson Bannow
10:30
Social Vulnerability And Hemophilia Care And Outcomes
Pooja Vijayvargiya1, Binh Le2, Christine L. Kempton1, 3, Vanessa R. Byams2, Brandi Dupervil2, Meredith Oakley2, Stacey A. Fedewa1, 3
1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States, 2Division of Blood Disorders and Public Health Genomics, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, United States, 3Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, United States

10:45
Heavy Menstrual Bleeding May Be Driven By Localized Endometrial Coagulopathy
Bethany T Samuelson Bannow1, Leslie Myatt2, Alison Edelman2
1Hemostasis & Thrombosis Center at Oregon Health & Science University, Portland, OR, United States, 2Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, United States

11:00
Agnostic Identification Of Plasma Biomarkers For Postpartum Hemorrhage Risk
Stephanie E. Reitsma1, Julia R. Barsoum2, Kirk C. Hansen3, Monika Dzieciatkowska3, Andra H. James4, Kjersti M. Aagaard5, Homa K. Ahmadzia2, Alisa S. Wolberg1
1Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States, 2Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, The George Washington University School of Medicine and Health Science, Washington, DC, United States, 3Biochemistry and Molecular Genetics, The University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 4Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, and Department of Medicine under Hematology, Duke University School of Medicine, Durham, NC, United States, 5Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States

11:15
Individual Pharmacokinetic Evaluation Of Fixed-Sequence Single-Dose Octocog Alfa, Rurioctocog Alfa Pegol, And Efanesoctocog Alfa In Adults With Severe Hemophilia A
Janice M. Staber1, Toshko Lissitchkov2, Anthony Chan3, Andrew Wilson4, Jennifer Dumont4, Annemieke Willemze 5
1Division of Hematology/Oncology, Department of Pediatrics, Carver College of Medicine, University of Iowa Stead Family Children's Hospital, Iowa City, IA, United States, 2Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia, Bulgaria, 3McMaster Children’s Hospital, McMaster University, Hamilton, ON, Canada, 4Sanofi, Cambridge, MA, United States, 5Sanofi, Amsterdam, Netherlands

10:30 - 11:30 AMSheraton Ballroom IV-V
Short Talks - Thrombosis - Special Populations

Chair(s): Gabriela Cesarman-Maus
10:30
Reclassification Of Antiphospholipid Antibody Syndrome According To The 2023 Acr/Eular Guidance In A Pharmacist Directed Anticoagulation Clinic
Catherine DeFazio1, Lara Horvath1, Jennifer Morgan1, Meaghan Murphy1, Ashley Shtoyko1, Elizabeth Phillips2
1SUNY Upstate Medical University, Syracuse, NY, United States, 2St. John Fisher University, Wegmans School of Pharmacy, Rochester, NY, United States

10:45
Understanding Primary Antiphospholipid Syndrome: Correlating Antiphospholipid Antibodies Profile And Titers With Thrombotic And Hematological Activity
Amaya Llorente-Chávez, Rodrigo Figueroa-Méndez, Gabriela A. Hernández-Molina, Alfonso Orozco-Collazo
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Mexico City , Mexico

11:!5
Health Literacy In Pediatric Thrombosis Patients And Parents/Caregivers
Athena Mancini, Denise Bastas, Sindi Mukaj, Gina Wong, Leonardo R. Brandão, Jennifer Vincelli , Diandra Rollan, M. Laura Avila
The Hospital for Sick Children, Toronto, ON, Canada

11:00
Nationally Representative Data On Co-Diagnosis, Mortality And Healthcare Burden Of Venous Thromboembolism In Hospitalized Covid-19 Patients: Results From The National Inpatient Sample
Giuseppe Maiocco1, Krish Khurana2, Nareg H. Roubinian3, Stephanie Bitner1, Waqas Azhar1, Hareena Sangha4, Nikhil Gupta5, Evan M. Bloch6, Michael B. Streiff6, Aaron A. R. Tobian6, Ruchika Goel1, 6, 7
1Southern Illinois University School of Medicine, Springfield, IL, United States, 2SIU School of Medicine P4P program, Springfield, IL, United States, 3Vitalant Research Institute, San Francisco, CA, United States, 4University of Texas Southwestern School of Medicine, Dallas, TX, United States, 5Case Western Reserve University School of Medicine, Cleveland, OH, United States, 6Johns Hopkins University School of Medicine, Baltimore, MD, United States, 7Vitalant Corporate Medical Affairs, Scottsdale, AZ, United States

10:30 - 11:30 AMChicago Ballroom VII
Short Talks - Insights on Platelet Biology

Chair(s): Cathy Hayward
10:30
Evaluating Diagnostic Algorithms For Heparin-Induced Thrombocytopenia Using Two Combined Rapid Automated Assays
Anna-Lise Bissola1,2, Yi Zhang1,3, Madison Cranstone2,4, Donald Arnold1,2, Ishac Nazy1,2
11. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada, 2Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 3. Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada, 32. Michael G. DeGroote Centre for Transfusion Research, McMaster University, 4. Department of Statistics and Actuarial Science, University of Waterloo,, Hamilton, ON, Canada, 41. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada, 51. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada

10:45
Dna Damage Repair Inhibition: A Catalyst For Enhanced Megakaryopoiesis And Thrombopoiesis
Roelof H Bekendam1,2, Andrew Stone1, Clementine Payne1, Virginia Camacho1, Isabelle Becker1, Estelle Carminita1, Maria Barrachina1, Kellie Machlus1, Joseph Italiano1
1Vascular Biology Program, Boston Children's Hospital, Boston, MA, United States, 2Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States

11:00
Novel Mechanism Of Thrombosis And Hemostasis Involving Platelet Alpha-Dystroglycan
Viktor Prifti1,2, Aron A. Shoara2,3, Reid C. Gallant4, Sladjana Slavkovic2,3, Kanwal Singh3, Margaret Rand1, Walter Kahr5, Yiming Wang2, Heyu Ni1,2,3
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 2Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, ON, Canada, 3Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, 4Department of Medicine, University of Toronto, Toronto, ON, Canada, 5Department of Biochemistry, University of Toronto, Toronto, ON, Canada

11:15
Unc9426, A Selective Tyro3 Inhibitor, Decreases Human Platelet Activation And Increases Survival In A Murine Pulmonary Embolism Model
Samantha Judd1, Stephanie Springborn1, Adam Kidwell1, Deborah DeRyckere2, Douglas K. Graham2, Xiaodong Wang3, Brian Branchford1
1Versiti Blood Research Institute, Wauwatosa, WI, United States, 2Aflac Cancer and Blood Disorders Center and Children's Healthcare of Atlanta, Atlanta, GA, United States, 3Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States

11:45 - 1:00 PMSheraton Ballroom IV-V
Shared decision making between patients and clinicians

Chair(s): Leslie Lake
11:45
How Can Clinicians Help Patients Make Decisions That Align With Their Values?
Nadine Shehata

12:10
Shared Decision Making When There Are Limited Data - Hemophilia Gene Therapy
Lindsey George

12:35
Patient Involvement In Guidelines - The Experience With The Ash Pediatric Vte Guideline
Sara Vesely